Document:

Amended and Restated Investors' Rights Agreement

 Exhibit 4.1 
  

 
  

JUNO THERAPEUTICS, INC. 

THIRD AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

August 1, 2014 

 TABLE OF CONTENTS 

 

									
	 	  	 	    	 	  	Page	 
	 Section 1 Definitions
	  	 	1	  
				
		  	1.1	    	 Certain Definitions
	  	 	1	  
		
	 Section 2 Registration Rights
	  	 	4	  
				
		  	2.1	    	 Requested Registration
	  	 	4	  
		  	2.2	    	 Company Registration
	  	 	6	  
		  	2.3	    	 Registration on Form S-3
	  	 	7	  
		  	2.4	    	 Expenses of Registration
	  	 	8	  
		  	2.5	    	 Registration Procedures
	  	 	8	  
		  	2.6	    	 Indemnification
	  	 	10	  
		  	2.7	    	 Information by Holder
	  	 	11	  
		  	2.8	    	 Rule 144 Reporting
	  	 	12	  
		  	2.9	    	 Market Stand-Off Agreement
	  	 	12	  
		  	2.10	    	 Delay of Registration
	  	 	13	  
		  	2.11	    	 Transfer or Assignment of Registration Rights
	  	 	13	  
		  	2.12	    	 Limitations on Subsequent Registration Rights
	  	 	13	  
		  	2.13	    	 Termination of Registration Rights
	  	 	13	  
		
	 Section 3 Covenants of the Company
	  	 	13	  
				
		  	3.1	    	 Basic Financial Information and Inspection Rights
	  	 	14	  
		  	3.2	    	 Inspection
	  	 	15	  
		  	3.3	    	 Board Observer
	  	 	15	  
		  	3.4	    	 Confidentiality
	  	 	16	  
		  	3.5	    	 Insurance
	  	 	16	  
		  	3.6	    	 Proprietary Invention and Assignment Agreements
	  	 	16	  
		  	3.7	    	 “Bad Actor” Notice
	  	 	17	  
		  	3.8	    	 Termination of Covenants
	  	 	17	  
		
	 Section 4 Right of First Option
	  	 	17	  
				
		  	4.1	    	 Right of First Option
	  	 	17	  
		
	 Section 5 Restrictions on Transfer
	  	 	20	  
				
		  	5.1	    	 Limitations on Disposition
	  	 	20	  
		
	 Section 6 Miscellaneous
	  	 	22	  
				
		  	6.1	    	 Amendment
	  	 	22	  
		  	6.2	    	 Notices
	  	 	23	  
		  	6.3	    	 Governing Law
	  	 	23	  
		  	6.4	    	 Successors and Assigns
	  	 	23	  
		  	6.5	    	 Entire Agreement
	  	 	24	  
		  	6.6	    	 Delays or Omissions
	  	 	24	  
		  	6.7	    	 Severability
	  	 	24	  
		  	6.8	    	 Titles and Subtitles
	  	 	24	  
		  	6.9	    	 Counterparts
	  	 	24	  
		  	6.10	    	 Telecopy Execution and Delivery
	  	 	24	  
		  	6.11	    	 Jurisdiction; Venue
	  	 	24	  

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	  	 	    	 	  	Page	 
		  	6.12	    	 Further Assurances
	  	 	25	  
		  	6.13	    	 Termination Upon Change of Control
	  	 	25	  
		  	6.14	    	 Conflict
	  	 	25	  
		  	6.15	    	 Attorneys’ Fees
	  	 	25	  
		  	6.16	    	 Aggregation of Stock
	  	 	25	  
		  	6.17	    	 Jury Trial
	  	 	25	  

  
 -ii- 

 JUNO THERAPEUTICS, INC. 

THIRD AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

This Third Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of August 1,
2014, and is between Juno Therapeutics, Inc., a Delaware corporation (f/k/a FC Therapeutics, Inc.) (the “Company”), and the persons and entities listed on Exhibit A (each, an “Investor” and
collectively, the “Investors”). 
 RECITALS 

A. Certain of the Investors are party to the Investors’ Rights Agreement, dated as of October 16, 2013, as amended and restated on
November 21, 2013 and on April 24, 2014, between the Company and the Investors party thereto (the “Prior Agreement”). 

B. As of the date hereof, the Company has entered into a Series B Preferred Stock Purchase Agreement (the “Stock Purchase
Agreement”), between the Company and the Investors listed on the Schedule of Investors thereto (the “Series B Investors”), pursuant to which the Company has agreed to sell, and the Series B Investors have agreed
to purchase shares of the Series B Preferred Stock of the Company. 
 C. The Company and the Investors desire to amend and restate the Prior
Agreement in order to, among other things, join the Series B Investors as Investors hereunder, and desire that this Agreement supersede and replace the Prior Agreement in its entirety. 

The parties therefore agree as follows: 

SECTION 1 
 DEFINITIONS

 1.1 Certain Definitions. As used in this Agreement, the following terms shall have the meanings set forth below: 

(a) “Asset Purchase Agreement” means the Asset Purchase Agreement, dated September 30, 2013, between the Company
and ZetaRx. 
 (b) “Bad Actor Disqualification” means any “bad actor” disqualification described in
Rule 506(d)(1)(i) through (viii) under the Securities Act. 
 (c) “Commission” shall mean the Securities
and Exchange Commission or any other federal agency at the time administering the Securities Act. 
 (d) “Common
Stock” means the Common Stock of the Company. 
 (e) “Conversion Stock” shall mean shares of Common
Stock issued upon conversion of the Preferred Stock. 

  
 -1- 

 (f) “Exchange Act” shall mean the Securities Exchange Act of 1934, as
amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(g) “FHCRC Side Letter” shall mean the side letter, between Fred Hutchinson Cancer Research Center
(“FHCRC”) and the Company, dated as of October 16, 2013. 
 (h) “Holder” shall mean any
Investor who holds Registrable Securities for so long as it holds Registrable Securities and any holder of Registrable Securities to whom the registration rights conferred by this Agreement have been duly and validly transferred in accordance with
Section 2.11 of this Agreement. 
 (i) “Indemnified Party” shall have the meaning set forth in
Section 2.6(c). 
 (j) “Indemnifying Party” shall have the meaning set forth in Section 2.6(c). 

(k) “Initial Public Offering” shall mean the closing of the Company’s first firm commitment underwritten public
offering of the Company’s Common Stock registered under the Securities Act. 
 (l) “Initiating Holders” shall
mean any Holder or Holders who in the aggregate hold not less than a majority of the outstanding Registrable Securities. 
 (m)
“Investors” shall mean the persons and entities listed on Exhibit A. 
 (n) “MSKCC Side
Letter” shall mean the side letter, between Memorial Sloan-Kettering Cancer Center (“MSKCC”) and the Company, dated as of November 21, 2013. 

(o) “New Securities” shall have the meaning set forth in Section 4.1(c). 

(p) “Other Shares” shall mean shares of Common Stock, other than Registrable Securities, with respect to which
registration rights have been granted. 
 (q) “Preferred Stock” shall mean the Series A Preferred Stock, the Series
A-1 Preferred Stock, the Series A-2 Preferred Stock and the Series B Preferred Stock of the Company. 
 (r) “Registrable
Securities” shall mean (i) shares of Common Stock issued or issuable pursuant to the conversion of the Shares, (ii) any Common Stock issued as a dividend or other distribution with respect to or in exchange for or in
replacement of the shares referenced in (i) above, (iii) any shares of Common Stock issued or issuable to FHCRC pursuant to the FHCRC Side Letter, (iv) any shares of Common Stock issued to ZetaRx pursuant to the Asset Purchase
Agreement and (v) any shares of Common Stock issued or issuable to MSKCC pursuant to the MSKCC Side Letter; provided, however, that Registrable Securities shall not include any shares of Common Stock described in clause
(i)-(v) above which have previously been registered or which have been sold to the public either pursuant to a registration statement or Rule 144, or which have been sold in a private transaction in which the transferor’s rights under
this Agreement are not validly assigned in accordance with this Agreement. 
 (s) The terms “register,”
“registered” and “registration” shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations
thereunder, and the declaration or ordering of the effectiveness of such registration statement. 

  
 -2- 

 (t) “Registration Expenses” shall mean all expenses incurred in effecting
any registration pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company and one special counsel for the Holders,
blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling Expenses, fees and disbursements of other counsel for the Holders and the compensation of
regular employees of the Company, which shall be paid in any event by the Company. 
 (u) “Restricted Securities”
shall mean any Preferred Stock and Registrable Securities required to bear the first legend set forth in Section 5.1(c). 
 (v)
“Rule 144” shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

(w) “Rule 145” shall mean Rule 145 as promulgated by the Commission under the Securities Act, as such Rule
may be amended from time to time, or any similar successor rule that may be promulgated by the Commission 
 (x) “Securities
Act” shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(y) “Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable
to the sale of Registrable Securities and fees and disbursements of counsel for any Holder (other than the fees and disbursements of one special counsel to the Holders included in Registration Expenses). 

(z) “Series A Preferred Stock” shall mean the shares of Series A Preferred Stock issued pursuant to the Asset
Purchase Agreement, the Series A Preferred Stock Purchase Agreement, dated October 16, 2013, between the Company and the Investors listed on the Schedule of Investors thereto, or pursuant to the Second Series A Preferred Stock Purchase
Agreement, dated December 16, 2013, between the Company and the Investors listed on the Schedule of Investors thereto. 
 (aa)
“Series A-1 Preferred Stock” shall mean the shares of Series A-1 Preferred Stock issued pursuant to the Asset Purchase Agreement. 

(bb) “Series A-2 Preferred Stock” shall mean the shares of Series A-2 Preferred Stock issued pursuant to the
Series A-2 Preferred Stock Purchase Agreement, dated April 24, 2014, between the Company and the Investors listed on the Schedule of Investors thereto. 

(cc) “Series B Preferred Stock” shall mean the shares of Series B Preferred Stock issued pursuant to the Stock
Purchase Agreement. 
 (dd) “Shares” shall mean the Company’s Series A Preferred Stock, Series A-1 Preferred
Stock, Series A-2 Preferred Stock and Series B Preferred Stock. 
 (ee) “Stock Purchase Agreement” shall have the
meaning set forth in the Recitals. 
 (ff) “Withdrawn Registration” shall mean a forfeited demand registration under
Section 2.1 in accordance with the terms and conditions of Section 2.4. 
 (gg) “ZetaRx” shall mean ZetaRx
Biosciences, Inc. 

  
 -3- 

 SECTION 2 

REGISTRATION RIGHTS 

2.1 Requested Registration. 

(a) Request for Registration. Subject to the conditions set forth in this Section 2.1, if the Company shall receive from
Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration with respect to all or a part of the Registrable Securities (such request shall state the number of shares of Registrable Securities to
be disposed of and the intended methods of disposition of such shares by such Initiating Holders), the Company will: 
 (i) promptly give
written notice of the proposed registration to all other Holders; and 
 (ii) as soon as practicable, file and use its commercially
reasonable efforts to effect such registration (including, without limitation, filing post-effective amendments, appropriate qualifications under applicable blue sky or other state securities laws, and appropriate compliance with the Securities Act)
and to permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such
request as are specified in a written request received by the Company within twenty (20) days after such written notice from the Company is mailed or delivered. 

(b) Limitations on Requested Registration. The Company shall not be obligated to effect, or to take any action to effect, any
such registration pursuant to this Section 2.1: 
 (i) Prior to the earlier of (A) the four (4) year anniversary of the date
of this Agreement or (B) one hundred eighty (180) days following the effective date of the first registration statement filed by the Company covering an underwritten offering of any of its securities to the general public (or the
subsequent date on which all market stand-off agreements applicable to the offering have terminated); 
 (ii) If the Initiating Holders,
together with the holders of any other securities of the Company entitled to inclusion in such registration statement, propose to sell Registrable Securities and such other securities (if any) pursuant to a registered offering that is listed on
either the NASDAQ Stock Market, The Nasdaq Global Select Market, The Nasdaq Global Market, The Nasdaq Capital Market, the New York Stock Exchange or any United States national securities exchange affiliated therewith, and any of their successors,
the aggregate proceeds of which (after deduction for underwriter’s discounts and expenses related to the issuance) are less than $50,000,000; 

(iii) In any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting
such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(iv) After the Company has initiated two such registrations pursuant to this Section 2.1 (counting for these purposes only
(x) registrations which have been declared or ordered effective and pursuant to which securities have been sold, and (y) Withdrawn Registrations); 

  
 -4- 

 (v) During the period starting with the date sixty (60) days prior to the Company’s
good faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of, a Company-initiated registration (or ending on the subsequent date on which all market stand-off agreements applicable
to the offering have terminated); provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or 

(vi) If the Initiating Holders propose to dispose of shares of Registrable Securities that may be registered on Form S-3 pursuant to a request made under Section 2.3. 
 (c) Deferral. If
(i) in the good faith judgment of the board of directors of the Company (the “Board”), the filing of a registration statement covering the Registrable Securities would be materially detrimental to the Company and the
Board concludes, as a result, that it is in the best interests of the Company to defer the filing of such registration statement at such time, and (ii) the Company shall furnish to such Holders a certificate signed by the President of the
Company stating that in the good faith judgment of the board of directors of the Company, it would be materially detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, in the best
interests of the Company to defer the filing of such registration statement, then (in addition to the limitations set forth in Section 2.1(b)(v) above) the Company shall have the right to defer such filing for a period of not more than ninety
(90) days after receipt of the request of the Initiating Holders, and, provided further, that the Company shall not defer its obligation in this manner more than once in any twelve-month period. 

(d) Other Shares. The registration statement filed pursuant to the request of the Initiating Holders may, subject to the
provisions of Section 2.1(e), include other shares of Common Stock, and may include securities of the Company being sold for the account of the Company. 

(e) Underwriting. If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of
an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.1 and the Company shall include such information in the written notice given pursuant to Section 2.1(a)(i). The right of any
Holder to include all or any portion of its Registrable Securities in such a registration pursuant to this Section 2.1 shall be conditioned upon such Holder’s participation in such an underwriting and the inclusion of such Holder’s
Registrable Securities to the extent provided herein. If the Company shall request inclusion in any registration pursuant to Section 2.1 of securities being sold for its own account, or if other persons shall request inclusion in any
registration pursuant to Section 2.1, the Initiating Holders shall, on behalf of all Holders, offer to include such securities in the underwriting and such offer shall be conditioned upon the participation of the Company or such other persons
in such underwriting and the inclusion of the Company’s and such person’s other securities of the Company and their acceptance of the further applicable provisions of this Section 2 (including Section 2.9). The Company shall
(together with all Holders and other persons proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for such
underwriting by a majority in interest of the Initiating Holders, which underwriters are reasonably acceptable to the Company. 

Notwithstanding any other provision of this Section 2.1, if the underwriters advise the Initiating Holders in writing that marketing
factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so included shall be allocated as follows: (i) first, among all Holders requesting to include Registrable Securities in
such registration statement based on the pro rata percentage of Registrable Securities held by such Holders, assuming conversion; and (ii) second, to the Company, which the Company may allocate, at its discretion, for its own account, or
for the account of other holders or employees of the Company. 

  
 -5- 

 If a person who has requested inclusion in such registration as provided above does not agree to
the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriter or the Initiating Holders. The securities so excluded shall also be withdrawn from registration. Any Registrable
Securities or other securities excluded or withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to be included in such registration was
previously reduced as a result of marketing factors pursuant to this Section 2.1(e), then the Company shall then offer to all Holders who have retained rights to include securities in the registration the right to include additional Registrable
Securities in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among such Holders requesting additional inclusion, as set forth above. 

2.2 Company Registration. 

(a) Company Registration. If the Company shall determine to register any of its securities either for its own account or the
account of a security holder or holders, other than a registration pursuant to Section 2.1 or 2.3, a registration relating solely to employee benefit plans, a registration relating to the offer and sale of debt securities, a registration
relating to a corporate reorganization or other Rule 145 transaction, or a registration on any registration form that does not permit secondary sales, the Company will: 

(i) promptly give written notice of the proposed registration to all Holders; and 

(ii) use its commercially reasonable efforts to include in such registration (and any related qualification under blue sky laws or other
compliance), except as set forth in Section 2.2(b) below, and in any underwriting involved therein, all of such Registrable Securities as are specified in a written request or requests made by any Holder or Holders received by the Company
within twenty (20) days after such written notice from the Company is mailed or delivered. Such written request may specify all or a part of a Holder’s Registrable Securities. 

(b) Underwriting. If the registration of which the Company gives notice is for a registered public offering involving an
underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.2(a)(i). In such event, the right of any Holder to registration pursuant to this Section 2.2 shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company and the other holders of securities of the Company with registration rights to participate therein distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the
representative of the underwriter or underwriters selected by the Company. 
 Notwithstanding any other provision of this Section 2.2,
if the underwriters advise the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) exclude all Registrable Securities from, or
limit the number of Registrable Securities to be included in, the registration and underwriting. The Company shall so advise all holders of securities requesting registration, and the number of shares of securities that are entitled to be included
in the registration and underwriting shall be allocated, as follows: (i) first, to the Company for securities being sold for its own account, and (ii) second, to the Holders requesting to include Registrable Securities in such registration
statement based on the pro rata percentage of Registrable Securities held by such Holders, assuming conversion; provided, however, that no such reduction shall reduce the value of the Registrable Securities of the Holders included in
such registration below fifty percent (50%) percent of the total value of securities included in such registration, unless such offering is the Company’s Initial Public Offering and such registration does not include shares of any other
selling stockholders (excluding shares registered for the account of the Company), in which event any or all of the Registrable 

  
 -6- 

 
Securities of the Holders may be excluded. In no event will shares of any other selling stockholder be included in such registration that would reduce the number of shares which may be included
by Holders without the written consent of Holders of not less than a majority of the Registrable Securities proposed to be sold in the offering. 

If a person who has requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such
person shall also be excluded therefrom by written notice from the Company or the underwriter. The Registrable Securities or other securities so excluded shall also be withdrawn from such registration. Any Registrable Securities or other securities
excluded or withdrawn from such underwriting shall be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares of Registrable Securities to be included in such registration was previously reduced
as a result of marketing factors pursuant to Section 2.2(b), the Company shall then offer to all persons who have retained the right to include securities in the registration the right to include additional securities in the registration in an
aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among the persons requesting additional inclusion, in the manner set forth above. 

(c) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it
under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. 

2.3 Registration on Form S-3.

(a) Request for Form S-3 Registration. After its initial public offering, the Company shall use its commercially reasonable
efforts to qualify for registration on Form S-3 or any comparable or successor form or forms. After the Company has qualified for the use of Form S-3, in addition to the rights contained in the foregoing provisions of this Section 2 and subject
to the conditions set forth in this Section 2.3, if the Company shall receive from a Holder or Holders of Registrable Securities a written request that the Company effect any registration on Form S-3 or any similar short form registration
statement with respect to all or part of the Registrable Securities (such request shall state the number of shares of Registrable Securities to be disposed of and the intended methods of disposition of such shares by such Holder or Holders), the
Company will take all such action with respect to such Registrable Securities as required by Section 2.1(a)(i) and 2.1(a)(ii). 
 (b)
Limitations on Form S-3 Registration. The Company shall not be obligated to effect, or take any action to effect, any such registration pursuant to this Section 2.3: 

(i) In the circumstances described in either Sections 2.1(b)(i), 2.1(b)(iii) or 2.1(b)(v); 

(ii) If the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to
sell Registrable Securities and such other securities (if any) on Form S-3 at an aggregate price to the public of less than $2,000,000; or 

(iii) If, in a given twelve-month period, the Company has previously effected one (1) such registration in such period. 

(c) Deferral. The provisions of Section 2.1(c) shall apply to any registration pursuant to this Section 2.3. 

  
 -7- 

 (d) Underwriting. If the Holders of Registrable Securities requesting registration
under this Section 2.3 intend to distribute the Registrable Securities covered by their request by means of an underwriting, the provisions of Section 2.1(e) shall apply to such registration. Notwithstanding anything contained herein to
the contrary, registrations effected pursuant to this Section 2.3 shall not be counted as requests for registration or registrations effected pursuant to Section 2.1. 

2.4 Expenses of Registration. All Registration Expenses incurred in connection with registrations pursuant to Sections 2.1, 2.2
and 2.3 shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Sections 2.1 and 2.3 if the registration request is subsequently
withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered or because a sufficient number of Holders shall have withdrawn so that the minimum offering conditions set forth in Sections 2.1 and 2.3 are no
longer satisfied (in which case all participating Holders shall bear such expenses pro rata among each other based on the number of Registrable Securities requested to be so registered), unless the Holders of a majority of the Registrable
Securities agree to forfeit their right to a demand registration pursuant to Section 2.1; provided, however, in the event that a withdrawal by the Holders is based upon material adverse information relating to the Company that is
different from the information known or available (upon request from the Company or otherwise) to the Holders requesting registration at the time of their request for registration under Section 2.1, such registration shall not be treated as a
counted registration or Withdrawn Registration for purposes of Section 2.1, even though the Holders do not bear the Registration Expenses for such registration. All Selling Expenses relating to securities registered on behalf of the Holders
shall be borne by the Company. 
 2.5 Registration Procedures. In the case of each registration effected by the Company pursuant
to Section 2, the Company will keep each Holder advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the Company will use its commercially reasonable efforts to: 

(a) Keep such registration effective for a period ending on the earlier of the date which is sixty (60) days from the effective date of
the registration statement or such time as the Holder or Holders have completed the distribution described in the registration statement relating thereto; 

(b) To the extent the Company is a well-known seasoned issuer (as defined in Rule 405 under the Securities Act) (a
“WKSI”) at the time any request for registration is submitted to the Company in accordance with Section 2.3, (i) if so requested, file an automatic shelf registration statement (as defined in Rule 405 under the
Securities Act) (an “automatic shelf registration statement”) to effect such registration, and (ii) remain a WKSI (and not become an ineligible issuer (as defined in Rule 405 under the Securities Act)) during the period
during which such automatic shelf registration statement is required to remain effective in accordance with this Agreement; 
 (c) Prepare
and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect
to the disposition of all securities covered by such registration statement for the period set forth in subsection (a) above; 
 (d)
Furnish such number of prospectuses, including any preliminary prospectuses, and other documents incident thereto, including any amendment of or supplement to the prospectus, as a Holder from time to time may reasonably request; 

(e) Use its reasonable best efforts to register and qualify the securities covered by such registration statement under such other securities
or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; provided, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent
to service of process in any such states or jurisdictions; 

  
 -8- 

 (f) Notify each seller of Registrable Securities covered by such registration statement at any
time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement
of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and following such notification promptly prepare
and furnish to such seller a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing; 

(g) If at any time when the Company is required to re-evaluate its WKSI status for purposes of an automatic shelf registration statement used
to effect a request for registration in accordance with Section 2.3 (i) the Company determines that it is not a WKSI, (ii) the registration statement is required to be kept effective in accordance with this Agreement, and
(iii) the registration rights of the applicable Holders have not terminated, promptly amend the registration statement onto a form the Company is then eligible to use or file a new registration statement on such form, and keep such registration
statement effective in accordance with the requirements otherwise applicable under this Agreement; 
 (h) If (i) a registration made
pursuant to a shelf registration statement is required to be kept effective in accordance with this Agreement after the third anniversary of the initial effective date of the shelf registration statement and (ii) the registration rights of the
applicable Holders have not terminated, file a new registration statement with respect to any unsold Registrable Securities subject to the original request for registration prior to the end of the three year period after the initial effective date
of the shelf registration statement, and keep such registration statement effective in accordance with the requirements otherwise applicable under this Agreement; 

(i) Use its commercially reasonable efforts to furnish, on the date that such Registrable Securities are delivered to the underwriters for
sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in
an underwritten public offering, addressed to the underwriters, if any, and reasonably satisfactory to a majority in interest of the Holders requesting registration of Registrable Securities and (ii) a “comfort” letter dated as of
such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters;

 (j) Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (k) Cause all such
Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities issued by the Company are then listed; and 

(l) In connection with any underwritten offering pursuant to a registration statement filed pursuant to Section 2.1, enter into an
underwriting agreement in form reasonably necessary to effect the offer and sale of Common Stock, provided such underwriting agreement contains reasonable and customary provisions, and provided further, that each Holder participating in such
underwriting shall also enter into and perform its obligations under such an agreement. 

  
 -9- 

 2.6 Indemnification.

(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors and partners,
legal counsel, accountants, investment managers and investment advisors and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification or compliance has been
effected pursuant to this Section 2, and each underwriter, if any, and each person who controls within the meaning of Section 15 of the Securities Act any underwriter, against all expenses, claims, losses, damages and liabilities (or
actions, proceedings or settlements in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any registration statement, any prospectus
included in the registration statement, any issuer free writing prospectus (as defined in Rule 433 of the Securities Act), any issuer information (as defined in Rule 433 of the Securities Act) filed or required to be filed pursuant to
Rule 433(d) under the Securities Act or any other document incident to any such registration, qualification or compliance prepared by or on behalf of the Company or used or referred to by the Company, (ii) any omission (or alleged
omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation (or alleged violation) by the Company of the Securities Act, any state securities laws
or any rule or regulation thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any offering covered by such registration, qualification or compliance, and the Company will reimburse each
such Holder, each of its officers, directors, partners, legal counsel, accountants, investment managers and investment advisors and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any
legal and any other expenses reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage, liability or action; provided that the Company will not be liable in any such case to the extent that
any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement or omission based upon written information furnished to the Company by such Holder, any of such Holder’s officers, directors, partners, legal
counsel or accountants, any person controlling such Holder, such underwriter or any person who controls any such underwriter, and stated to be specifically for use therein; and provided, further that, the indemnity agreement contained
in this Section 2.6(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld). 

(b) To the extent permitted by law, each Holder will (severally and not jointly), if Registrable Securities held by such Holder are included
in the securities as to which such registration, qualification or compliance is being effected, indemnify and hold harmless the Company, each of its directors, officers, partners, legal counsel and accountants and each underwriter, if any, of the
Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, each other such Holder, and each of their officers, directors
and partners, and each person controlling each other such Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a
material fact contained or incorporated by reference in any prospectus, offering circular or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification or compliance, or
(ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and such Holders, directors, officers, partners,
legal counsel and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the
extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity
with written information furnished to the Company by such Holder and stated to be specifically for use therein; provided, however, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any such
claims, losses, damages or liabilities (or actions in respect 

  
 -10- 

 
thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld); and provided that in no event shall any indemnity under this
Section 2.6 exceed the net proceeds from the offering received by such Holder, except in the case of fraud or willful misconduct by such Holder. 

(c) Each party entitled to indemnification under this Section 2.6 (the “Indemnified Party”) shall give notice to
the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to
assume the defense of such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified
Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such party’s expense; and provided further that the failure of any Indemnified Party to give notice as provided
herein shall not relieve the Indemnifying Party of its obligations under this Section 2.6, to the extent such failure is not prejudicial. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of
each Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect
to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with defense of
such claim and litigation resulting therefrom. 
 (d) If the indemnification provided for in this Section 2.6 is held by a court of
competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall
contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the
Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and
of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or
by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. No Holder will be required under this Section 2.6(d) to contribute any amount in
excess of the difference between (i) the net proceeds from the offering received by such Holder and (ii) any amounts paid or payable by such Holder pursuant to Section 2.6(b), except in the case of fraud or willful misconduct by such
person or entity. No person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent
misrepresentation. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

2.7 Information by Holder. Each Holder of Registrable Securities shall furnish to the Company such information regarding such
Holder and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance referred to in this Section 2. 

  
 -11- 

 2.8 Rule 144 Reporting. With a view to making available the benefits of certain
rules and regulations of the Commission that may permit the sale of the Restricted Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to: 

(a) Make and keep adequate current public information with respect to the Company available in accordance with Rule 144 under the
Securities Act, at all times from and after the effective date of the first registration under the Securities Act filed by the Company for an offering of its securities to the general public; 

(b) File with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act at any time after it has become subject to such reporting requirements; and 
 (c) So long as a holder owns any Restricted
Securities, furnish to the holder forthwith upon written request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90) days following the effective date
of the first registration statement filed by the Company for an offering of its securities to the general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the
most recent annual or quarterly report of the Company, and such other reports and documents so filed as a holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a holder to sell any such securities
without registration. 
 2.9 Market Stand-Off Agreement. If requested by the Company and an underwriter of Common Stock (or other
securities) of the Company, each Investor shall not sell or otherwise transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any Common
Stock (or other securities) of the Company held by such holder (other than those included in the registration or purchased in the relevant offering or on the open market) during the period from the public filing of a registration statement of the
Company filed under the Securities Act that includes securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act through the end of the 180-day period following the effective date of
the registration statement for the Initial Public Offering. The obligations described in this Section 2.9 shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be
promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions and may stamp each such certificate with the second
legend set forth in Section 5.1(c) with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of the applicable period. Each holder of Preferred Stock agrees to execute a market standoff
agreement with said underwriters in customary form consistent with the provisions of this Section 2.9. Notwithstanding the foregoing: the foregoing provisions shall be applicable only if (i) all officers and directors of the Company are
subject to the same restrictions and the Company uses commercially reasonable efforts to subject all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion
into Common Stock of all outstanding Preferred Stock) to the same restrictions and (ii) the Company uses its commercially reasonable efforts to obtain the agreement of the managing underwriter to (x) periodic early releases of portions of
the securities subject thereto upon the occurrence of certain specified events, and (y) in the event of any early release, all Investors will be released on a pro rata basis from such market stand-off agreements. If any of the obligations
described in this Section 2.9 are waived or terminated with respect to any of the securities of any such Holder, executive officer, director or greater-than-one-percent stockholder (in any such case, the “Released
Securities”), the foregoing provisions shall be waived or terminated, as applicable, to the same extent and with respect to the same percentage of securities of each Holder as the percentage of Released Securities represent with respect
to the securities held by the applicable Holder, executive officer, director or greater-than-one-percent stockholder. 

  
 -12- 

 2.10 Delay of Registration. No holder of Preferred Stock shall have any right to take
any action to restrain, enjoin, or otherwise delay any registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.11 Transfer or Assignment of Registration Rights.

The rights to cause the Company to register securities granted to a Holder by the Company under this Section 2 may be transferred or
assigned by a Holder only to (A) a parent, subsidiary or other affiliate of the Holder, if the Holder is a corporation, (B) any of the Holder’s partners, members or other equity owners, or retired partners, retired members or other
equity owners, or to the estate of any of the Holder’s partners, members or other equity owners or retired partners, retired members or other equity owners, (C) a venture capital or other investment fund that is controlled by or under
common control with one or more general partners or managing members of, or shares the same management company or investment advisor with, the Holder, (D) an acquiror of not less than 1,000,000 shares of Registrable Securities (as presently
constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like) and (E) if such Holder is ZBS Holdings, LLC (as successor to ZetaRx), to ZetaRx’s former stockholders; provided
that (i) such transfer or assignment of Registrable Securities is effected in accordance with the terms of Section 5.1 of this Agreement, that certain Right of First Refusal and Co-Sale Agreement, dated as of the date hereof, between the
Company and the Common Holders and Investors (each as defined in such agreement) party thereto (the “Right of First Refusal and Co-Sale Agreement”), and applicable securities laws, (ii) the Company is given written
notice prior to said transfer or assignment, stating the name and address of the transferee or assignee and identifying the securities with respect to which such registration rights are intended to be transferred or assigned and (iii) the
transferee or assignee of such rights assumes in writing the obligations of such Holder under this Agreement, including without limitation the obligations set forth in Section 2.9. 

2.12 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the
prior written consent of Holders holding at least a majority of the Registrable Securities (excluding any of such shares held by any Holders whose rights to request registration or inclusion in any registration pursuant to this Section 2 have
terminated in accordance with Section 2.13), enter into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder any registration rights the terms of which are senior to the
registration rights granted to the Holders hereunder. 
 2.13 Termination of Registration Rights. The right of any Holder to
request registration or inclusion in any registration pursuant to Sections 2.1, 2.2 or 2.3 shall terminate on the earlier of (i) such date, on or after the closing of the Company’s Initial Public Offering, on which all shares of
Registrable Securities held or entitled to be held upon conversion by such Holder may immediately be sold under Rule 144 during any ninety (90) day period without the requirement for the Company to be in compliance with the current public
information required under Rule 144(c)(1), and (ii) five (5) years after the closing of the Company’s Initial Public Offering. 

SECTION 3 

COVENANTS OF THE COMPANY 

The Company hereby covenants and agrees, as follows: 

  
 -13- 

 3.1 Basic Financial Information and Inspection Rights. 

(a) Basic Financial Information. Following the date hereof, the Company will furnish the following reports to each Holder who
owns at least 20% of the Shares and/or Conversion Stock (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like): 

(i) As soon as practicable after the end of each fiscal year of the Company, and in any event within one hundred twenty (120) days after
the end of each fiscal year of the Company (which deadline may be extended by the Board of Directors to up to one hundred and fifty (150) days after the end of each fiscal year), consolidated balance sheet of the Company and its subsidiaries,
if any, as at the end of such fiscal year, and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year, prepared in accordance with U.S. generally accepted accounting principles consistently
applied, which shall be audited and certified by independent public accountants. 
 (ii) As soon as practicable after the end of the first,
second and third quarterly accounting periods in each fiscal year of the Company, and in any event within ninety (90) days after the end of the first, second, and third quarterly accounting periods in each fiscal year of the Company,
respectively, an unaudited consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such quarterly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if
any, for such period, prepared in accordance with U.S. generally accepted accounting principles consistently applied, subject to changes resulting from normal year-end audit adjustments and which statements may not contain all footnotes required by
U.S. generally accepted accounting principles; except that, with respect to the quarterly accounting period ended March 31, 2014, such balance sheet and statements do not need to be delivered within ninety (90) days after the end of that
period, but shall be delivered as soon as practicable. 
 (iii) As soon as practicable, but in any event within ninety (90) days
following the beginning of each fiscal year, a budget and business plan for such fiscal year (collectively, the “Budget”), approved by the Board, including balance sheets, income statements, and statements of cash flow. 

The Company will also furnish the reports referred to in clauses (i) and (ii) above to each Holder who owns at least 300,000 shares
of Series B Preferred Stock and/or Conversion Stock underlying the Series B Preferred Stock (subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like) or is a registered investment company under the
Investment Company Act of 1940, as amended. 
 (b) FHCRC and MSKCC Financial Information. The Company will furnish to each of
FHCRC and MSKCC (i) annually, the information described in Sections 3(a)(i) and (iii) above and (ii) (a) on the date each year that is six months after the information described in clause (i) of this sentence is furnished to
each of FHCRC and MSKCC, and (b) on each date on which any of FHCRC or MKSCC receives a notice pursuant to Section 4.1(d) of this Agreement, Section 2.2 of the Right of First Refusal and Co-Sale Agreement or with respect to a Change
in Control Transaction (as defined in the Voting Agreement) such interim financial reports described in Section 3(a)(ii) above as are available at such time; provided, however, that in each case, each of FHCRC and MSKCC shall
ensure that such information is kept confidential and that such information is only disclosed to the following individuals: (x) with respect to FHCRC, the President and Director, Executive Vice Presidents, Chief Financial Officer and General
Counsel of FHCRC, and any individual serving on the Executive Committee of the Board of FHCRC; and (y) with respect to MSKCC, the Chief Executive Officer, Chief Financial Officer, Vice President—Research and Technology Management, and
Executive Director, Office of Technology Development of MSKCC, and any individual serving on the Executive Committee of the Board of MSKCC. 

  
 -14- 

 3.2 Inspection. The Company shall permit CL Alaska L.P., or its affiliated entities that
are Holders (“CL Alaska”) (provided that the Board of Directors has not reasonably determined that CL Alaska is a competitor of the Company) and ARCH Venture Fund VII, L.P. or its affiliated entities
(“ARCH”) (provided that the Board of Directors has not reasonably determined that ARCH is a competitor of the Company), at such holder’s expense, to visit and inspect the Company’s properties; examine its books of
account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the holder; provided, however, that the Company shall not be
obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless CL Alaska and ARCH, respectively, agree to execute an
enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

The Company agrees that management of the Company will have a call with each Holder who owns, or any investment management company that
advises Holders that own, at least 2,500,000 shares of Series B Preferred Stock and/or Conversion Stock underlying the Series B Preferred Stock (subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the
like), on a quarterly basis during each year to discuss the Company’s affairs, finances and accounts. Each such call shall be at a mutually agreeable time. The Company shall not be obligated pursuant to this paragraph to provide access to any
information that it reasonably and in good faith considers to be a trade secret or confidential information (unless the Holder or associated investment management company, as applicable, agrees to execute an enforceable confidentiality agreement, in
form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Board Observer. 
 (a)
Board Observer. The Company shall permit each of (i) a representative reasonably acceptable to the Company (the “Series A-1 Representative”) designated from time to time by the holders of Series A-1
Preferred Stock of the Company (the “Series A-1 Preferred Holders”), which Series A-1 Representative shall initially be David Dull, (ii) two representatives reasonably acceptable to the Company designated by CL
Alaska (the “CL Alaska Representatives”), which CL Alaska Representatives shall initially be John Cochran and David Fallace, (iii) a representative reasonably acceptable to the Company designated from time to time by
FHCRC (the “FHCRC Representative”) and (iv) a representative reasonably acceptable to the Company designated from time to time by MSKCC (the “MSKCC Representative,” and each of the MSKCC
Representative, the Series A-1 Representative, the CL Alaska Representative and the FHCRC Representative, a “Representative”), which MSKCC Representative shall initially be Gregory Raskin, in each case, to attend all meetings
(whether in person, telephonic or otherwise) of the Board and each Board committee (whether standing or ad hoc) in a non-voting, observer capacity. In addition, the Company shall provide to each Representative, concurrently with the members of the
Board and each Board committee (whether standing or ad hoc) or the committees thereof, as applicable, and in the same manner, notice of such meeting and a copy of all materials provided to such members, including minutes of meetings and all
materials provided to such members in connection with any action to be taken by the Board or the committees thereof, as applicable, without a meeting. 

(b) Expenses. The Company agrees to reimburse the reasonable and documented travel and related expenses of each Representative
incurred in connection with such person’s attendance of Board and applicable committee meetings of the Company. 
 (c)
Exclusion. If the Board determines in good faith that exclusion of the Representatives or omission of the information to be provided to a Representative pursuant to this Agreement is necessary in order to (i) preserve the attorney
client privilege, or (ii) avoid a conflict of interest between the Company and any Investor, including any Series A-1 Preferred Holder, then the Company shall have the right to exclude the Representative from portions of meetings of the Board
or the committees thereof in which such information is discussed, as applicable, or omit to provide the representative with certain information, in each case to the extent deemed necessary by the Board. 

  
 -15- 

 3.4 Confidentiality. Anything in this Agreement to the contrary notwithstanding, no
Preferred Stock holder or Representative by reason of this Agreement shall have access (whether by access to documents or observer’s attendance of Board meetings) to any trade secrets or classified information of the Company (unless the holder
or Representative agrees to execute an enforceable confidentiality agreement, in form acceptable to the Company). In the absence of such an executed confidentiality agreement, holder or Representative may be denied access to any confidential
documents or information and/or a Representative may be excluded from the portion of Board meeting or committees thereof attended by such Representative during which such confidential information is discussed. In addition, the Company shall not be
required to comply with any information or board observer rights of Section 3 (including, without limitation providing competitively or commercially sensitive information that could be used to the Company’s commercial or strategic
disadvantage) in respect of any Preferred Stock holder whom the Company reasonably determines to be a competitor or an officer, employee, director or holder of more than ten percent (10%) of a competitor. Each Preferred Stock holder
acknowledges that the information received by them pursuant to this Agreement may be confidential and for its use only, and it will not use such confidential information in violation of the Exchange Act or reproduce, disclose or disseminate such
information to any other person (other than its employees or agents having a need to know the contents of such information, and its attorneys, accountants and investment advisors who are subject to confidentiality obligations with respect to such
information no less strict than the terms of the Section 3.4), except in connection with the exercise of rights under this Agreement, unless the Company has made such information available to the public generally; provided, however, that a
Preferred Stock holder may disclose confidential information (i) to any prospective purchaser of any Preferred Stock from such holder, if such prospective purchaser agrees to be bound by provisions of this Section 3.4, (ii) to any
partner, member, or stockholder of such holder in the ordinary course of business, provided that such holder informs such person that such information is confidential and such person agrees in writing to maintain the confidentiality of such
information; (iii) as may otherwise be required by law, provided that the holder promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure; or (iv) in the case of the
Series A-1 Representative, to any manager of ZBS Holdings, LLC, that executes a confidentiality agreement with respect to such information in a form reasonably satisfactory to the Company, which confidentiality agreement shall include, without
limitation, a representation that such director or manager, as applicable, is not an officer, employee, director or holder of more than ten percent (10%) of any entity or person involved in the any business relating to immunotherapy for human
disease; and provided, further, that in no event shall any Preferred Stock holder or any Representative disclose confidential information to entity or person whom the Company reasonably determines to be a competitor or an officer,
employee, director or holder of more than ten percent (10%) of a competitor. 
 3.5 Insurance. The Company shall maintain
in full force and effect, (i) term life insurance, payable to the Company, on the life of its chief executive officer in the amount of $1,000,000 and (ii) directors and officers liability insurance (which shall also cover any entity deemed
a controlling person of the Company under Section 15 of the Securities Act or Section 20 of the Exchange Act), in each case from financially sound and reputable insurers and in amount determined by a majority of the Company’s board of
directors, in any event not less than $3,000,000. 
 3.6 Proprietary Invention and Assignment Agreements. Each technical
employee and managerial employee of the Company has executed or shall execute one or more agreements for the benefit of the Company with respect to confidential information, assignment of inventions and non-competition and non-solicitation. 

  
 -16- 

 3.7 “Bad Actor” Notice. Each party to this Agreement will promptly notify
each other party to this Agreement in writing if it or, to its knowledge, any person specified in Rule 506(d)(1) under the Securities Act becomes subject to any Bad Actor Disqualification; provided, however, that, with respect to
the Investors, such obligation under this Section 3.7 shall apply only if such Investor beneficially owns 20% or more of the Company’s outstanding voting securities, calculated on the basis of voting power. 

3.8 Termination of Covenants. The covenants set forth in Section 3.1, the rights of Investors (other than CL Alaska) in
Section 3.2, and the rights of the Series A-1 Preferred Holders, Series A-2 Investors, FHCRC and MSKCC in Section 3.3 shall terminate and be of no further force and effect after the closing of the Company’s Initial Public
Offering. The rights of CL Alaska in Sections 3.2 and 3.3 shall terminate and be of no further force and effect upon the latter of: (a) the closing of the Company’s Initial Public Offering, or (b) CL Alaska owning less than 10% of all
the Company shares of Common Stock outstanding (assuming full conversion or exercise of all outstanding Company convertible securities, rights, options and warrants). 

SECTION 4 
 RIGHT OF
FIRST OPTION 
 4.1 Right of First Option.

(a) The Company hereby grants to each Holder the right of first option to purchase a number of shares (rounded down to the nearest whole share)
equal to its pro rata share of New Securities (as defined in Section 4.1(c)) which the Company may, from time to time, propose to sell and issue on or after the date of this Agreement, subject to Sections 4.1(b)-(e). A Holder’s
pro rata share, for purposes of this right of first option, is equal to the ratio of (a) the number of shares of Common Stock owned by such Holder immediately prior to the issuance of New Securities (assuming full conversion of the
Shares and full conversion or exercise of all outstanding convertible securities, rights, options and warrants held by said Holder) to (b) the total number of shares of Common Stock outstanding immediately prior to the issuance of New
Securities (assuming full conversion of the Shares and full conversion or exercise of all outstanding convertible securities, rights, options and warrants). Each Holder (including CL Alaska) shall have a right of over-allotment such that if any
Holder fails to exercise its rights hereunder to purchase its full pro rata share of New Securities, the other Holders may purchase such Holder’s unsubscribed portion on a pro rata basis; provided, however, that where a
Holder informs the Company during the Election Period that such Holder intends to exercise its rights to purchase its full pro rata share of New Securities, but such Holder (or one or more designees of such Holder as provided in
Section 4.1(d)) does not purchase such pro rata share for whatever reason, the Company may determine either (i) not to sell the unpurchased amounts or (ii) to offer unpurchased amounts to the other Holders in accordance with
their over-allotment rights. 
 (b) In addition to the rights granted pursuant to Section 4.1(a) above, the Company hereby grants to CL
Alaska, the right of first option to purchase an additional number of New Securities, in each issuance of New Securities after the date of this Agreement, equal to the amount by which the CL Alaska Participation Shares exceeds CL Alaska’s
pro rata share as calculated in accordance with Section 4.1(a), subject to Section 4.1(c)-(e); provided, however, that the number of New Securities that CL Alaska shall have the right of first option to purchase in any issuance
pursuant to Sections 4.1(a) and (b) shall in no event exceed the amount by which (i) the total number of shares of New Securities issued in such issuance exceeds (ii) the aggregate number of New Securities subject to the right of
first option which each other Holder elects to purchase pursuant to Section 4.1(a). The “CL Alaska Participation Shares” with respect to any new issuance shall be a number of shares (rounded down to the nearest whole
share) of New Securities equal to the lesser of (a) 64.71% of the New Securities issued by the Company in such issuance and (b) a number of New Securities equal to the positive difference, if any, by which (1) a number equal to 50% of
the 

  
 -17- 

 
number of shares of Common Stock outstanding immediately following such issuance of New Securities (assuming full conversion of the Shares and New Securities and full conversion or exercise of
all outstanding Company convertible securities, rights, options and warrants) exceeds (2) the number of shares of Common Stock owned by CL Alaska immediately prior to such issuance of New Securities (assuming full conversion of the Shares and
full conversion or exercise of all outstanding convertible securities, rights, options and warrants held by CL Alaska), such positive difference rounded to the next whole share. 

(c) “New Securities” shall mean any capital stock (including Common Stock and/or Preferred Stock) of the Company
whether now authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and securities of any type whatsoever that are, or may become, exercisable or convertible into capital stock; provided that
the term “New Securities” does not include: 
 (i) any shares of the Series B Preferred Stock authorized by the
Company’s certificate of incorporation as of the date hereof, other than 14,005,369 shares of Series B Preferred Stock to be offered by the Company in the Second Closing (as defined in the Stock Purchase Agreement) (as adjusted for any stock
splits, stock dividends, combinations, subdivisions, recapitalizations and the like), and, in each case, the Conversion Stock issuable with respect thereto, provided that the calculation of pro rata shares and the CL Alaska
Participation Shares under Sections 4.1(a) and 4.1(b) with respect to such 14,005,369 shares of Series B Preferred Stock to be offered by the Company in the Second Closing shall be made as of immediately prior to the Initial Closing (as defined in
the Stock Purchase Agreement); 
 (ii) securities issued or issuable to officers, employees, directors, consultants, placement agents, and
other service providers of the Company (or any subsidiary) pursuant to stock grants, option plans, purchase plans, agreements or other employee stock incentive programs or arrangements approved by the board of directors of the Company including the
ARCH Designee (as defined in that certain Voting Agreement entered into by and among the Company, the Series A Investors, the Series A-1 Preferred Holders, the Series A-2 Investors, the Series B Investors and the Founders, each as defined therein,
on the date hereof (the “Voting Agreement”)); 
 (iii) securities issued pursuant to the conversion or exercise of
any outstanding convertible or exercisable securities as of the date of this Agreement; 
 (iv) securities issued or issuable as a dividend
or distribution on Preferred Stock of the Company or pursuant to any similar event; 
 (v) securities issued or issuable pursuant to the
acquisition of another corporation by the Company by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, in each case for consideration other than cash, provided, that such issuances
are approved by the board of directors of the Company; 
 (vi) securities issued or issuable to banks, equipment lessors, real property
lessors, financial institutions or other persons engaged in the business of making loans pursuant to a debt financing, commercial leasing or real property leasing transaction approved by the board of directors of the Company including the ARCH
Designee; 
 (vii) securities or rights, options or warrants to acquire any security of the Company issued or granted in connection with
sponsored research, collaboration, technology license, development, OEM, marketing, or other similar agreements or strategic partnerships in which the Company enters into a simultaneous business relationship with the investor, approved by the board
of directors of the Company including the ARCH Designee; 

  
 -18- 

 (viii) securities issued to suppliers or third party service providers in connection with the
provision of goods or services pursuant to transactions approved by the board of directors of the Company; and 
 (ix) any right, option or
warrant to acquire any security convertible into the securities excluded from the definition of New Securities pursuant to subsections (i) through (viii) above. 

(d) In the event the Company proposes to undertake an issuance of New Securities, it shall give each Holder written notice of its intention,
describing the type of New Securities, and their price and the general terms upon which the Company proposes to issue the same. Each Holder shall have twenty (20) days after any such notice is mailed or delivered to agree to purchase all or any
portion of such Holder’s pro rata share (or, in the case of CL Alaska, its pro rata share and any CL Alaska Participation Shares) of such New Securities and to indicate whether such Holder desires to exercise its over-allotment
option for the price and upon the terms specified in the notice by giving written notice to the Company, in substantially the form attached as Schedule 1, and stating therein the quantity of New Securities to be purchased. Each such Holder may
specify that the New Securities purchased by such Holder pursuant to this Section 4.1 may be purchased and/or issued and delivered to one or more designees of such Holder; provided, however, that any such purchaser designee must
be reasonably acceptable to the Company; provided, further in no event shall the Company be required to issue any shares to any such designee if the Company believes, upon advice of counsel, that such issuance shall not be exempt from
registration under applicable federal and state securities laws, or that such issuance would otherwise violate such laws; and provided, further, that the Company may require, as a condition of any issuance of New Securities to any such
designee, that the designee execute such documents as the Company may reasonably request in connection with such issuance, including documents intended to verify such designee’s status as an “accredited investor” pursuant to Rule 501
of the Securities Act, documents otherwise reasonably necessary, in the determination of counsel to the Company, for such issuance to be made in compliance with applicable federal and state securities laws, and counterpart signature pages to this
Agreement, the Voting Agreement and the Right of First Refusal and Co-Sale Agreement. For avoidance of doubt, any former stockholder of ZetaRx to which the issuance of shares would be exempt under applicable federal and state securities laws and
that satisfies the other requirements of this Section 4.1(d) shall be reasonably acceptable to the Company as a purchaser designee. 

(e) In the event the Holders fail to exercise fully the right of first option and over-allotment rights, if any within said twenty
(20) day period (the “Election Period”), the Company shall have ninety (90) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at
all, within ninety (90) days from the date of said agreement) to sell that portion of the New Securities with respect to which the Holders’ right of first option set forth in this Section 4.1 was not exercised, at a price and upon
terms no more favorable to the purchasers thereof than specified in the Company’s notice to Holders delivered pursuant to Section 4.1(d). In the event the Company has not sold such New Securities within such ninety (90) day period
following the Election Period, or such ninety (90) day period following the date of said agreement, the Company shall not thereafter issue or sell any New Securities, without first again offering such securities to the Holders in the manner
provided in this Section 4.1. 
 (f) The right of first option granted under this Agreement shall expire upon the Company’s
Initial Public Offering. The right of first option granted under this Agreement shall not be applicable to the Company’s Initial Public Offering; provided, however, that the Company hereby grants to CL Alaska the right to purchase
a number of New Securities issued in the Company’s Initial Public Offering with an aggregate purchase price (as determined based on the per share price-to-the-public in such Initial Public Offering) (the “IPO Price”) of
up to $25,000,000; provided, however, that such right shall not be exercisable by CL Alaska unless it agrees to purchase a number of shares of Common Stock with an aggregate purchase price of at least $10,000,000 (the “CL
Alaska IPO Right”). CL Alaska must provide 

  
 -19- 

 
notice to the Company of its intention to exercise the IPO Right within ten (10) days following receipt by CL Alaska of notice delivered by the Company pursuant to Section 2.2(a) of the
proposed Initial Public Offering; provided, however, that CL Alaska may, at its election, specify in such notice that it instead elects to enter into good faith negotiations with the Company regarding a “side car” private
offering conducted simultaneously with the Company’s Initial Public Company for the same amounts set forth in this Section 4.1(f), such private offering to be subject to further conditions and adjustments; provided, further,
however, that in no event shall the Company take any action pursuant to this Section 4.1(f) or any other provision of this Agreement unless such action is in compliance with all applicable federal and state securities laws. 

(g) A Holder that is (or, as a result of the exercise of its rights to purchase New Securities in accordance with this Section 4, will
become) a beneficial owner of 20% or more of the Company’s outstanding voting securities, calculated on the basis of voting power, will not have a right to purchase New Securities in accordance with this Section 4 if, and for so long as,
(i) the Holder, (ii) any of its directors, officers (as defined under Rule 16a-1 promulgated under the Exchange Act), other officers of the Holder that may serve as a director or officer of the Company, general partners or managing members
or (iii) any beneficial owner of the Holder which is (or, as a result of Holder’s purchase of New Securities hereunder, will become) a 20% beneficial owner of the voting securities of the Company (in accordance with Rule 506(d) of the
Securities Act) is subject to any Bad Actor Disqualification, except as set forth in Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Securities Act. 

SECTION 5 

RESTRICTIONS ON TRANSFER 

5.1 Limitations on Disposition. Each person owning of record shares of Preferred Stock or Registrable Securities (collectively,
the “Securities”) or any assignee of record of Securities hereby agrees not to make any disposition of all or any portion of any Securities unless and until: 

(a) there is then in effect a registration statement under the Securities Act of 1933, as amended (the “Securities
Act”), covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

(b) such holder shall have notified the Company of the proposed disposition, the transferee in such disposition has agreed in writing for the
benefit of the Company to take and hold such Securities subject to, and to be bound by, the terms and conditions set forth in this Agreement, including, without limitation, this Section 5.1 and Section 2.9, and such holder shall have
furnished the Company with (i) a statement of the circumstances surrounding the proposed disposition, and, at the expense of such holder or its transferee, with an opinion of counsel, reasonably satisfactory to the Company, that such
disposition will not require registration of such securities under the Securities Act or (ii) a “no action” letter from the Commission to the effect that the transfer of such securities without registration will not result in a
recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the holder of such Securities shall be entitled to transfer such Securities in accordance with the terms of the notice delivered by the Holder to the
Company. 
 Notwithstanding the provisions of Sections 5.1(a) and (b) above, no such registration statement, opinion of counsel or
“no action” letter shall be required by the Company: (i) for any transfer of any Securities in compliance with SEC Rule 144 or Rule 144A (and no notice to the Company shall be required for such transfers, except where an opinion of
counsel to the Company is requested or required by Holder or the Company’s transfer agent), (ii) a transfer not involving a change in beneficial ownership, (iii) for any transfer of any Securities by a holder that is a partnership,
limited liability company, a corporation or a venture capital or other investment fund to (A) a partner of such partnership, a member of such limited 

  
 -20- 

 
liability company or stockholder of such corporation, (B) a parent, subsidiary or other affiliate of such partnership, limited liability company or corporation (including, without
limitation, any affiliated investment fund of such holder), (C) a retired partner of such partnership or a retired member of such limited liability company, (D) the estate of any such partner, member or stockholder, or (E) a venture
capital or other investment fund that is controlled by or under common control with one or more general partners or managing members of, or shares the same management company or investment advisor with, such holder, (iv) for the transfer by
gift, will or intestate succession by any holder to his or her spouse or lineal descendants or ancestors or any trust for any of the foregoing or (v) transactions involving the distribution or transfer of Securities by ZBS Holdings, LLC (as
successor to ZetaRx) to ZetaRx’s former stockholders, provided, however, such distribution or transfer must comply with all applicable securities laws; provided that in the case of clauses (ii), (iii) and (iv) the transferee
agrees in writing to be subject to the terms of this Agreement to the same extent as if the transferee were an original Investor hereunder and the transfer was without consideration or at no greater than cost. 

(c) Each certificate representing Securities shall (unless otherwise permitted by the provisions of this Agreement) be stamped or otherwise
imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER
THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION
THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO (1) RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD
IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS’ RIGHTS AGREEMENT, AND (2) VOTING RESTRICTIONS AS SET FORTH IN A VOTING AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDERS OF THESE SHARES, COPIES OF WHICH MAY BE OBTAINED
AT THE PRINCIPAL OFFICE OF THE COMPANY. 
 Each Investor consents to the Company making a notation on its records and giving instructions to
any transfer agent of the Securities in order to implement the restrictions on transfer established in this Section 5.1. 
 (d) The
first legend referring to federal and state securities laws identified in Section 5.1(c) stamped on a certificate evidencing the Securities and the stock transfer instructions and record notations with respect to the Securities shall be removed
and the Company shall issue a certificate without such legend to the holder of Securities if (i) those securities are registered under the Securities Act, or (ii) the holder provides the Company with an opinion of counsel reasonably
acceptable to the Company to the effect that a sale or transfer of those securities may be made without registration or qualification. 

(e) Each Investor agrees not to make any sale, assignment, transfer, pledge or other disposition of any securities of the Company, or any
beneficial interest therein, to any person (other than the Company or an affiliate of the Company) that, to such Investor’s knowledge, is or has a beneficial owner that 

  
 -21- 

 
is (or, in either case, as a result of such proposed transfer will become) a beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of
voting power, unless and until the proposed transferee confirms to the reasonable satisfaction of the Company that neither: (i) the proposed transferee, (ii) any of its directors, officers (as defined under Rule 16a-1 promulgated under the
Exchange Act), other officers that may serve as a director or officer of the Company, general partners or managing members, nor (iii) any beneficial owner of such transferee that is (or as a result of such proposed transfer will become) a 20%
beneficial owner of the voting securities of the Company (in accordance with Rule 506(d) of the Securities Act) is subject to any Bad Actor Disqualification, except as set forth in Rule 506(d)(2)(ii) or (iii) or (d)(3) under the
Securities Act and disclosed, reasonably in advance of the transfer, in writing in reasonable detail to the Company. 
 SECTION 6

 MISCELLANEOUS 

6.1 Amendment. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended, waived, discharged
or terminated other than by a written instrument referencing this Agreement and signed by the Company and the Holders holding at least a majority of the Registrable Securities issued or issuable upon conversion of shares of Series A Preferred Stock,
Series A-2 Preferred Stock and Series B Preferred Stock, voting together as a single class and on an as-converted to Common Stock basis, (excluding any of such shares that have been sold to the public or pursuant to Rule 144, and excluding,
with respect to Section 2 (other than Sections 2.8 and 2.9), any of such shares held by any Holders whose rights to request registration or inclusion in any registration pursuant to Section 2 have terminated in accordance with
Section 2.13); provided, however, that Investors (as defined in the Stock Purchase Agreement) purchasing shares of Series B Preferred Stock pursuant to the Stock Purchase Agreement in a Closing after the Initial Closing (each
as defined in the Stock Purchase Agreement) may become parties to this Agreement, by executing a counterpart of this Agreement without any amendment of this Agreement pursuant to this paragraph or any consent or approval of any other Holder; and
provided, further, that if any amendment, waiver, discharge or termination operates in a manner that treats any Holder different from other Holders, the consent of such Holder shall also be required for such amendment, waiver,
discharge or termination; provided, further, that an amendment or waiver of a Holder’s right of first option pursuant to Section 4.1 that has the effect of reducing the number of New Securities that such Holder would
otherwise have a right of first option to purchase pursuant to Section 4.1 shall not be deemed to treat any Holder differently from other Holders if the right of first option of each other Holder with respect to such issuance is waived in a
proportionate manner, such that the Company shall commit to offer each Holder its pro rata share of (or, in the case of CL Alaska, the aggregate of its pro rata share and CL Alaska Participation Shares of) an identical amount of New Securities of
the same class or series. Any such amendment, waiver, discharge or termination effected in accordance with this paragraph shall be binding upon each Holder and each future holder of all such securities of Holder. Notwithstanding the foregoing, any
amendment or waiver of Section 2.9 or Section 3.1, or this sentence of Section 6.1, that has an adverse effect on the rights or obligations of a Holder that, together with its affiliates, holds at least 1,000,000 shares of Series B
Preferred Stock and/or Conversion Stock underlying the Series B Preferred Stock (subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like), shall not be effective against such Holder without such
Holder’s prior written consent. Each Holder acknowledges that, except to the extent provided above, by the operation of this paragraph, the holders of at least a majority of the Series A Preferred Stock, Series A-2 Preferred Stock and Series B
Preferred Stock, voting together as a single class and on an as-converted to Common Stock basis, (excluding any of such shares that have been sold to the public or pursuant to Rule 144, and excluding, with respect to Section 2 (other than
Sections 2.8 and 2.9), any of such shares held by any Holders whose rights to request registration or inclusion in any registration pursuant to Section 2 have terminated in accordance with Section 2.13) will have the right and power
to diminish or eliminate all rights of such Holder under this Agreement. 

  
 -22- 

 6.2 Notices. All notices and other communications required or permitted hereunder shall be
in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to an Investor or a Holder) or otherwise delivered by hand, messenger or courier service addressed: 

(a) if to an Investor, to the Investor’s address, facsimile number or electronic mail address as shown in the Stock Purchase Agreement or
Asset Purchase Agreement, as may be updated in accordance with the provisions hereof, 
 (b) if to any Holder, to such address, facsimile
number or electronic mail address as shown in the Company’s records, or, until any such Holder so furnishes an address, facsimile number or electronic mail address to the Company, then to the address of the last holder of such shares for which
the Company has contact information in its records; or 
 (c) if to the Company, to the attention of the General Counsel of the Company at
307 Westlake Avenue North, Suite 300, Seattle, WA 98109, e-mail: barney.cassidy@junotherapeutics.com, or at such other current address as the Company shall have furnished to the Investors or Holders, with a copy (which shall not constitute notice)
to Patrick J. Schultheis, Wilson Sonsini Goodrich & Rosati, P.C., 701 Fifth Avenue, Suite 5100, Seattle, WA 98104. 
 Each such
notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier
service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained
receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the
relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s next business day. 

Subject to the limitations set forth in Delaware General Corporation Law §232(e), each Investor and Holder consents to the delivery of
any notice to stockholders given by the Company under the Delaware General Corporation Law or the Company’s certificate of incorporation or bylaws by (i) facsimile telecommunication to the facsimile number set forth on Exhibit A (or
to any other facsimile number for the Investor or Holder in the Company’s records), (ii) electronic mail to the electronic mail address set forth on Exhibit A (or to any other electronic mail address for the Investor or Holder in the
Company’s records), or (iii) posting on an electronic network together with separate notice to the Investor or Holder of such specific posting. This consent may be revoked by an Investor or Holder by written notice to the Company and may
be deemed revoked in the circumstances specified in Delaware General Corporation Law §232. 
 6.3 Governing Law. This Agreement
shall be governed in all respects by the internal laws of the State of Delaware as applied to agreements entered into among Delaware residents to be performed entirely within Delaware, without regard to principles of conflicts of law which would
result in the application of the laws of another jurisdiction. 
 6.4 Successors and Assigns. This Agreement, and any and all rights,
duties and obligations hereunder, shall not be assigned, transferred, delegated or sublicensed by any Investor without the prior written consent of the Company; provided that transfers of Shares and all other rights and obligations under this
Agreement accompanying such transfer of Shares may be made pursuant to the provisions of Section 5 

  
 -23- 

 
without any additional Company consent pursuant to this Section 6.4. Any attempt by an Investor without such permission to assign, transfer, delegate or sublicense any rights, duties or
obligations that arise under this Agreement shall be void. Subject to the foregoing and except as otherwise provided herein, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs,
executors and administrators of the parties hereto. 
 6.5 Entire Agreement. This Agreement and the exhibits hereto constitute the
full and entire understanding and agreement between the parties with regard to the subjects hereof. No party hereto shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties,
representations or covenants except as specifically set forth herein. The Prior Agreement is superseded in its entirety. 
 6.6 Delays or
Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right,
power or remedy of such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single
breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any
waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise
afforded to any party to this Agreement, shall be cumulative and not alternative. 
 6.7 Severability. If any provision of this
Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court
will replace such illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable
provision. The balance of this Agreement shall be enforceable in accordance with its terms. 
 6.8 Titles and Subtitles. The titles
and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise provided,
refer to sections and paragraphs hereof and exhibits attached hereto. 
 6.9 Counterparts. This Agreement may be executed in any
number of counterparts, each of which shall be enforceable against the parties that execute such counterparts, and all of which together shall constitute one instrument. 

6.10 Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more
parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and
effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof. 

6.11 Jurisdiction; Venue. Each of the parties hereto hereby submits and consents irrevocably to the exclusive jurisdiction of, and
venue in, the courts in Wilmington, Delaware (or in the event of exclusive federal jurisdiction, the federal courts in Wilmington, Delaware) for the interpretation and enforcement of the provisions of this Agreement. Each of the parties hereto also
agrees that the jurisdiction over the person of 

  
 -24- 

 
such parties and the subject matter of such dispute shall be effected by the mailing of process or other papers in connection with any such action in the manner provided for in Section 6.2
or in such other manner as may be lawful, and that service in such manner shall constitute valid and sufficient service of process. 

6.12 Further Assurances. Each party hereto agrees to execute and deliver, by the proper exercise of its corporate, limited liability
company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be necessary to more fully effectuate this Agreement. 

6.13 Termination Upon Change of Control. Notwithstanding anything to the contrary herein, this Agreement (excluding any then-existing
obligations) shall terminate upon (a) the acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company is party (including, without limitation, any stock acquisition,
reorganization, merger or consolidation but excluding any sale of stock for capital raising purposes) other than a transaction or series of transactions in which the holders of the voting securities of the Company outstanding immediately prior to
such transaction continue to retain (either by such voting securities remaining outstanding or by such voting securities being converted into voting securities of the surviving entity), as a result of shares in the Company held by such holders prior
to such transaction, at least fifty percent (50%) of the total voting power represented by the voting securities of the Corporation or such surviving entity outstanding immediately after such transaction or series of transactions; or (b) a
sale, lease, exclusive license or other conveyance of all substantially all of the assets of the Company. Notwithstanding the foregoing, (i) the rights and obligations of the Investors under Section 2 shall not terminate if, following any
such transaction, the Investors hold “restricted securities” (as defined under Rule 144) and (ii) the rights of the Investors under Section 3.1(a) shall not terminate if, following any such transaction, the Investors hold equity
in an entity that is not subject to the reporting requirements of Section 13(a) or 15(d) of the Exchange Act. 
 6.14 Conflict.
In the event of any conflict between the terms of this Agreement and the Company’s certificate of incorporation or its bylaws, the terms of the Company’s certificate of incorporation or its bylaws, as the case may be, will control. 

6.15 Attorneys’ Fees. In the event that any suit or action is instituted to enforce any provision in this Agreement, the
prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable
fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 
 6.16
Aggregation of Stock. All securities held or acquired by affiliated entities (including affiliated venture capital or other investment funds) or persons shall be aggregated together for purposes of determining the availability of any rights
under this Agreement. 
 6.17 Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW,
ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS AGREEMENT. 

(signature page follows) 

  
 -25- 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	JUNO THERAPEUTICS, INC.
	a Delaware corporation

 
			
		
	By:	 	 /s/ Hans Bishop

			
		
	Name:	 	 Hans Bishop

 
			
		
	Title:	 	 Chief Executive Officer

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	  

	
	  

	Signature
	
	  

	Print name of signatory, if signing for an entity
	
	  

	Print title of signatory, if signing for an entity

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	FIDELITY SELECT PORTFOLIOS:
	BIOTECHNOLOGY PORTFOLIO
	
	 /s/ Stacie M. Smith

			
		
	Name:	 	 Stacie M. Smith

			
		
	Title:	 	 Deputy Treasurer

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	 FIDELITY ADVISOR SERIES VII:

FIDELITY ADVISOR BIOTECHNOLOGY FUND

	
	 /s/ Stacie M. Smith

			
		
	 Name:
	 	 Stacie M. Smith

			
		
	 Title:
	 	 Deputy Treasurer

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	 FIDELITY GROUP TRUST FOR

EMPLOYEE BENEFIT PLANS:
 FIDELITY GROWTH COMPANY

COMMINGLED POOL

 
			
		
	By:	 	Fidelity Management & Trust Co.

 
			
	
	 /s/ Kenneth Robins

			
		
	Name:	 	 Kenneth Robins

 

			
		
	Title:	 	 Treasurer

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	 FIDELITY MT. VERNON STREET

TRUST: FIDELITY SERIES GROWTH
 COMPANY
FUND

	
	 /s/ Stacie M. Smith

			
		
	Name:	 	 Stacie M. Smith

			
		
	Title:	 	 Deputy Treasurer

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	 FIDELITY MT. VERNON STREET

TRUST: FIDELITY GROWTH COMPANY
 FUND

	
	 /s/ Stacie M. Smith

			
		
	 Name:
	 	 Stacie M. Smith

			
		
	 Title:
	 	 Deputy Treasurer

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	SMALLCAP WORLD FUND, INC.
		
	By:	 	Capital Research and Management Company
		
	Its:	 	Investment Advisor

 
			
		
	By:	 	 Kenneth

 
			
		
	Its:	 	 Sr. Vice President and Sr. Counsel

Fund Business Management Group

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	 WUXI PHARMATECH HEALTHCARE

FUND I L.P.

	
	 By WuXi PharmaTech Fund I General Partner

L.P., its general partner

	
	 By WuXi PharmaTech Investments (Cayman)

Inc., its general partner

 

			
	By:	 	 /s/ Ge Li

	Name: Ge Li
	Title: Director

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	 HAWKES BAY MASTER INVESTORS

(CAYMAN) LP

	
	 By: Wellington Management Company, LLP,

as investment adviser

	
	 /s/ Matthew N. Shea

			
		
	 Name:
	 	 Matthew N. Shea

			
		
	 Title:
	 	 Vice President & Counsel

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	 NORTH RIVER INVESTORS

(BERMUDA) L.P.

	
	 By: Wellington Management Company, LLP,

as investment adviser

 
			
	
	 /s/ Matthew N. Shea

			
		
	Name:	 	 Matthew N. Shea

			
		
	Title:	 	 Vice President & Counsel

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	SALTHILL INVESTORS (BERMUDA) L.P.
	
	By: Wellington Management Company, LLP, as investment adviser

 
			
	
	
/s/ Matthew N. Shea

 
			
		
	 Name:
	 	 Matthew N. Shea

			
		
	 Title:
	 	 Vice President & Counsel

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	NORTH RIVER PARTNERS, L.P.

 
			
	
	By: Wellington Management Company, LLP, as investment adviser

 
			
	
	 /s/ Matthew N. Shea

			
		
	 Name:
	 	 Matthew N. Shea

			
		
	 Title:
	 	 Vice President & Counsel

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	SALTHILL PARTNERS, L.P.

 
			
	
	By: Wellington Management Company, LLP, as investment adviser

 
			
	
	 /s/ Matthew N. Shea

			
		
	 Name:
	 	 Matthew N. Shea

			
		
	 Title:
	 	 Vice President & Counsel

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	RA CAPITAL HEALTHCARE FUND, LP

 
			
	
	 /s/ Peter Kolchinsky

			
	 Name:
	 	Peter Kolchinsky

 
			
	 Title:
	 	Manager

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	V-SCIENCES INVESTMENTS PTE LTD
	
	 /s/ Fidah Alsagoff

	Authorized Signatory
	
	 Fidah Alsagoff

	Print name of signatory
	
	 Authorised Signatory

	Print title of signatory

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	LEERINK HOLDINGS LLC
	
	 /s/ Timothy A.G. Gerhold

			
	Name:	 	Timothy A.G. Gerhold

 
			
	Title:	 	General Counsel

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	LEERINK SWANN CO-INVESTMENT FUND, LLC
	
	 /s/ Joseph R. Gentile

	Name:	 	 Joseph R. Gentile

	Title:	 	 Manager

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	JANUS GLOBAL LIFE SCIENCES FUND
	
	 /s/ Andrew Acker

	Name:	 	Andrew Acker

 
			
	Title:	 	Portfolio Manager

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	PFM HEALTHCARE MASTER FUND, L.P.
	
	 /s/ Yuan DuBord

	Name:	 	Yuan DuBord

 
			
	Title:	 	Chief Financial Officer

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	PFM HEALTHCARE PRINCIPALS FUND, L.P.

 
			
	
	 /s/ Yuan DuBord

	Name:	 	Yuan DuBord

 
			
	Title:	 	Chief Financial Officer

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	 ROCK SPRINGS CAPITAL MASTER FUND LP

By: Rock Springs GP LLC
 Its: General
Partner

 
			
		
	By:	 	 /s/ Graham McPhail

			
		
	Name:	 	 Graham McPhail

 

			
		
	Title:	 	 Member/Managing Director

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	 FORESITE CAPITAL FUND II, L.P.

By: Foresite Capital Management II, LLC
 Its: General
Partner

 
			
		
	 By:
	 	 /s/ Dennis D. Ryan

			
	 Name:
	 	Dennis D. Ryan

 
			
	 Title:
	 	Chief Financial Officer

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

					
	INVESTOR:
	
	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
	 By:
	 	Deerfield Mgmt, L.P.
		 	General Partner
		 	 By: J.E. Flynn Capital, LLC

		 	 General Partner

		
	 By:
	 	 /s/ David J. Clark

	 Name: David J. Clark

	 Title: Authorized Signatory

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

					
	INVESTOR:
	
	 DEERFIELD SPECIAL SITUATIONS INTERNATIONAL

MASTER FUND, L.P.

	 By:
	 	Deerfield Mgmt, L.P.
		 	General Partner
		 	 By: J.E. Flynn Capital, LLC

		 	 General Partner

		
	 By:
	 	 /s/ David J. Clark

	 Name: David J. Clark

	 Title: Authorized Signatory

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	ALEXANDRIA EQUITIES, LLC,
	a Delaware limited liability company
		
	By:	 	ALEXANDRIA REAL ESTATE
		 	EQUITIES, INC.
		 	a Maryland corporation, managing member

 
			
	
	 /s/ Dean A. Shigenaga

	Signature
	
	 Daen A. Shigenaga

	Print name of signatory, if signing for an entity
	
	 Chief Financial Officer

	Print title of signatory, if signing for an entity

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	 DULL FAMILY INVESTMENT TRUST
 U/D/T
DTD. DECEMBER 1, 2012

	
	 /s/ John C. Fossum

	Signature
	
	 John C. Fossum

	Print name of signatory, if signing for an entity
	
	 Trustee

	Print title of signatory, if signing for an entity

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	DULL-SHIELDKRET REVOCABLE TRUST DATED MARCH 14, 2003
	
	 /s/ David A. Dull

	Signature
	
	 David A. Dull

	Print name of signatory, if signing for an entity
	
	 Trustee

	Print title of signatory, if signing for an entity

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	 FRED HUTCHINSON CANCER RESEARCH

CENTER

	
	 /s/ R. C. Main

	(Signature)
	
	 Randall C. Main

	(Print name of signatory, if signing for an entity)
	
	 Vice President and CFO

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	NICOLAS J. HANAUER
	
	 /s/ Nicolas J. Hanauer

	(Signature)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	FCPH, LLC
	
	 /s/ Amir Nashat

	(Signature)
	
	 Amir Nashat

	(Print name of signatory, if signing for an entity)
	
	 Member

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	 WERNER F. WOLFEN, TRUSTEE OF THE

WOLFEN REVOCABLE TRUST DATED
 7/22/02

	
	 /s/ Werner F. Wolfen

	(Signature)
	
	 Werner F. Wolfen

	(Print name of signatory, if signing for an entity)
	
	 Trustee

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	WOLFEN FAMILY FOUNDATION
	
	 /s/ Werner F. Wolfen

	(Signature)
	
	 Werner F. Wolfen

	(Print name of signatory, if signing for an entity)
	
	 Trustee

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	 THE EDMUND AND ELLEN OLIVIER

REVOCABLE FAMILY TRUST DATED
 AUGUST 9,
2000

	
	 /s/ Edmund M. Olivier de Vezin

	(Signature)
	
	 Edmund Martin Olivier de Vezin

	(Print name of signatory, if signing for an entity)
	
	 Trustee

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	ARCH Venture Fund VII, L.P.

 
			
	By:	 	ARCH Venture Partners VII, L.P.
	Its:	 	General Partner
	By:	 	ARCH Venture Partners VII, LLC
	Its:	 	General Partner

 
			
	
	 /s/ Keith Crandell

	Managing Director
	
	 Keith Crandell

	(Print name of signatory)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	 MEMORIAL SLOAN-KETTERING CANCER

CENTER

	
	 /s/ Jason Klein

	Executive Director
	
	 Jason Klein

	(Print name of signatory)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	GE LI
	
	 /s/ Ge Li

	Signature

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	JOHN R. STUELPNAGEL TRUST
	
	 /s/ John R. Stuelpnagel

	Signature
	
	 John R. Stuelpnagel

	Print name of signatory, if signing for an entity
	
	 Trustee

	Print title of signatory, if signing for an entity

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	NICOLAS J. HANAUER
	
	 /s/ Nicolas J. Hanauer

	Signature

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	SETH GORDON
	
	 /s/ Seth Gordon

	(Signature)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	WS INVESTMENT COMPANY, LLC (2014A)
	
	 /s/ Patrick J. Schultheis

	Signature
	
	 Patrick J. Schultheis

	Print name of signatory, if signing for an entity
	
	 Member

	Print title of signatory, if signing for an entity

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	MEMORIAL SLOAN-KETTERING CANCER CENTER
	
	 /s/ Jason Klein

	(Signature)
	
	 Jason Klein

	(Print name of signatory, if signing for an entity)
	
	 Senior Vice President & CIO

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	I&M JUNO INVESTORS II
	
	 /s/ Ian C. Wiener

	(Signature)
	
	 Ian C. Wiener

	(Print name of signatory, if signing for an entity)
	
	 Managing General Partner

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	EXPLORE HOLDINGS, LLC
	
	 /s/ Paul Dauber

	(Signature)
	
	 Paul Dauber

	(Print name of signatory, if signing for an entity)
	
	 Manager

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	NEIL BRADSHAW
	
	 /s/ Neil Bradshaw

	(Signature)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	VCVC III LLC
	By:	 	VCVC Management III LLC, Its Manager
	By:	 	Cougar Investment Holdings LLC, Its Manager

 
	
	
	 /s/ Susan Drake

	(Signature)
	
	 Susan Drake

	(Print name of signatory, if signing for an entity)
	
	 Vice President

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	 CYNTHIA A. CRAWFORD, TRUSTEE OF

THE CRAWFORD/GERBER LIVING TRUST

DATED OCTOBER 7, 2009 AS AMENDED TO

BE HELD PURSUANT TO SCHEDULE C
 THEREOF AS THE SOLE AND
SEPARATE
 PROPERTY OF CYNTHIA A. CRAWFORD

	
	 /s/ Cynthia A. Crawford

	(Signature)
	
	 Cynthia A. Crawford

	(Print name of signatory, if signing for an entity)
	
	 Trustee

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	 ROTNER FAMILY TRUST DATED

AUGUST 14, 1998, AS AMENDED

	
	 /s/ Glenn F. Rotner

	Signature
	
	 Glenn F. Rotner

	Print name of signatory, if signing for an entity
	
	 Trustee

	Print title of signatory, if signing for an entity

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	TOM ALBERG
	
	 /s/ Tom Alberg

	(Signature)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	AKIRA MATSUNO
	
	 /s/ Akira Matsuno

	(Signature)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	 MORGAN STANLEY SMITH BARNEY
 LLC AS
CUSTODIAN FOR BERNARD
 CASSIDY IRA

	
	 /s/ Bernard J. Cassidy

	(Signature)
	
	 Bernard J. Cassidy

	Print name of signatory, if signing for an entity
	
	 IRA Owner

	Print title of signatory, if signing for an entity

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	JT LINE PARTNERS L.P.,
a Texas limited partnership
		
	By:	 	Bratton Capital Management, L.P., its General Partner
		 	By: Bratton Capital Inc., its General Partner
	
	 /s/ John S. Cochran

	(Signature)
	
	 John S. Cochran

	(Print name of signatory, if signing for an entity)
	
	 Vice-President

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

			
	INVESTOR:
	
	CL ALASKA L.P.
		
	By:	 	Crestline SI (GP), L.P.
	Its:	 	General Partner

 
			
		
	By:	 	 /s/ John S. Cochran

			
		
	Name:	 	 John S. Cochran

			
		
	Title:	 	 Vice President

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	ASGAARD FUND L.P.
	
	 /s/ Todd Binder

	(Signature)
	
	 Todd Binder

	(Print name of signatory, if signing for an entity)
	
	 Managing Partner

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	SAEED SY NIKSEFAT
	
	 /s/ Saeed Sy Niksefat

	Signature

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	HOWARD PIEN
	
	 /s/ Howard Pien

	Signature
	
	  

	Print name of signatory, if signing for an entity
	
	  

	Print title of signatory, if signing for an entity

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 The parties are signing this Third Amended and Restated Investors’ Rights Agreement as of
the date stated in the introductory clause. 
  

	
	INVESTOR:
	
	ZBS HOLDINGS, LLC
	
	 /s/ David A. Dull

	(Signature)
	
	 David A. Dull

	(Print name of signatory, if signing for an entity)
	
	 Manager

	(Print title of signatory, if signing for an entity)

 (Signature page to the Third Amended and Restated Investors’ Rights
Agreement) 

 SCHEDULE 1 

NOTICE AND WAIVER/ELECTION OF 

RIGHT OF FIRST OPTION 

I do hereby waive or exercise, as indicated below, my rights of first option under the Investors’ Rights Agreement dated as of
[                    ], 2014 (the “Agreement”): 

 

	1.	Waiver of 20 days’ notice period in which to exercise right of first option: (please check only one) 

  

	 	(    )	WAIVE in full, on behalf of all Holders, the 20-day notice period provided to exercise my right of first option granted under the Agreement. 

 

	 	(    )	DO NOT WAIVE the notice period described above. 

  

	2.	Issuance and Sale of New Securities: (please check only one) 

  

	 	(    )	WAIVE in full the right of first option granted under the Agreement with respect to the issuance of the New Securities. 

  

	 	(    )	ELECT TO PARTICIPATE in $             (please provide amount) in New Securities proposed to be issued by JUNO THERAPEUTICS, INC., a Delaware
corporation, representing LESS than my pro rata portion of the aggregate of $[            ] in New Securities being offered in the financing. 

 

	 	(    )	ELECT TO PARTICIPATE in $             in New Securities proposed to be issued by JUNO THERAPEUTICS, INC., a Delaware corporation, representing my FULL
pro rata portion of the aggregate of $[            ] in New Securities being offered in the financing. 

 

	 	(    )	ELECT TO PARTICIPATE in my full pro rata portion of the aggregate of $[            ] in New Securities being made available in the financing AND,
to the extent available, the greater of (x) an additional $             (please provide amount) or (y) my pro rata portion of any remaining investment amount
available in the event other Holders do not exercise their full rights of first option with respect to the $[            ] in New Securities being offered in the financing.

 Date:                  

 

	
	  

	(Print investor name)
	
	  

	(Signature)
	
	  

	(Print name of signatory, if signing for an entity)
	
	  

	(Print title of signatory, if signing for an entity)

 This is neither a commitment to purchase nor a commitment to issue the New Securities described above. Such
issuance can only be made by way of definitive documentation related to such issuance. The company will supply you with such definitive documentation upon request or if you indicate that you would like to exercise your first offer rights in whole or
in part.Exclusive License Agreement

 Exhibit 10.1 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 
 CONFIDENTIAL 

EXCLUSIVE LICENSE AGREEMENT 
 THIS
EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made this 1st day of November, 2009 (the “Effective Date”) by and between City of Hope, a California nonprofit public benefit corporation located at 1500 East Duarte Road,
Duarte, California 91010 (“COH”) and ZetaRx LLC, a Delaware limited liability company located at 9701 Wilshire Boulevard, Suite 1000 c/o Benmore Capital, Beverly Hills, CA 90212 (“Zeta”). COH and Zeta are each sometimes referred
to herein individually as a “Party” and together as the “Parties.” 
 RECITALS 

A. COH operates an academic research and medical center that encourages the use of its inventions, discoveries and intellectual property for the best interests
of the public. COH owns, or controls with the right to sub-license in the Field, as defined below, all right, title, and interest in the “Patent Rights” as defined below. 

B. Zeta is a company dedicated to the research, development, marketing and sale of products useful in the Field. To further these efforts, Zeta desires to
obtain from COH an exclusive license under the Patent Rights on the terms and conditions set forth below. 
 NOW, THEREFORE, for good and valuable
consideration the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
  

	1.	DEFINITIONS 

 1.1 “Affiliate” of a Party means any entity that
controls, is controlled by, or is under common control with such Party. In this context, “control” shall mean (1) ownership by one entity, directly or indirectly, of at least 50 percent of the voting stock of another entity;
(2) having the power to direct the management or policies of another entity, by contract or otherwise. 
 1.2 “Combination
Product” means a Licensed Product which incorporates or is co-packaged under a single label with one or more biologically active components, the manufacture, use or sale of which does not, in whole or part, infringe a Valid Claim
(“Other Actives”). 

  
 - 1 - 

 CONFIDENTIAL 
  

1.3 “Confidential Information” means all proprietary and non-public business or technical information, whether or not
patentable, disclosed by one Party to the other Party either in writing and marked “confidential” or disclosed orally and reduced to a writing marked “confidential” within 30 days after the initial oral disclosure.
Notwithstanding the foregoing, “Confidential Information” shall not include any information that: (i) was in the public domain as of the Effective Date or comes into the public domain during the term of this Agreement through no act
of the receiving Party; (ii) was independently known to the receiving Party as shown by the receiving Party’s written records prior to receipt from the disclosing Party, or made available to the receiving Party by a Third Party without any
violation of the obligations of such Third Party or the receiving Party to the other Party; (iii) is independently conceived, invented, or acquired by the receiving Party by persons who were not exposed to Confidential Information. 

1.4 “Field 1” means the use of a [***] for the treatment or prevention of disease in humans. 

1.5 “Field 2” means the use of a [***] for the treatment or prevention of disease in humans where said [***] has
been genetically engineered by any means other than through the [***]. 
 1.6 “First Qualified Financing”
means one or more transactions which result in aggregate net cash proceeds to Zeta of not less than $[***] (after payment of or accounting for all commissions, discounts, rebates, refunds or credits) in return for the issuance of membership units or
other equity in Zeta. 
 1.7 “License Year” means the period from the Effective Date through December 31, 2009 and each
calendar year thereafter. 
 1.8 “Licensed Product” means a member of Licensed Product Group 1 or License Product Group 2.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 2 - 

 CONFIDENTIAL 
  

1.9 “Licensed Product Group 1” means a compound (whether in the form of a kit, reagent, testing material, or otherwise), the
manufacture, use, or offer for sale of which, but for the license granted herein, would in whole or part infringe a Valid Claim in Patent Group 1 (and which may or may not infringe a Valid Claim in Patent Group 2). 

1.10 “Licensed Product Group 2” means a compound (whether in the form of a kit, reagent, testing material, or otherwise), the
manufacture, use, or offer for sale of which, but for the license granted herein, would in whole or part infringe a Valid Claim in Patent Group 2 but which would not infringe a Valid Claim in Patent Group 1. 

1.11 “Net Sales” means the gross amount invoiced by or on behalf of Zeta or a sub-licensee of Zeta on account of the sale,
use, transfer or other disposition or application of a Licensed Product to or by a Third Party, less reasonable, customary and documented deductions for any of the following: 

(i) rebates, allowances, charge-backs or discounts (including, without limitation, contractual discounts and allowances for Medicaid,
Medicare, Medi-Cal, managed care and third party insurance providers and the like), to the extent actually granted; 
 (ii) allowances or
credits actually granted to customers on account of recall, rejection or return of Licensed Products; 
 (iii) tariffs, duties, excise,
sales and value-added taxes and similar governmental charges actually paid (except income taxes); and 
 (iv) to the extent actually paid by
seller, reasonable charges for shipping and insuring the shipment of Licensed Product. 
 Sales and other transfers of Licensed Products
between or among Zeta and its sublicensees shall be excluded from the computation of Net Sales, except in those instances in which the sublicensee is also the end-user of the Licensed Product sold. Further, transfers of reasonable quantities of
Licensed Product by Zeta or a sublicensee of Zeta to a Third Party for use in the development of such Licensed 

  
 - 3 - 

 CONFIDENTIAL 
  

Product (and not for resale) and transfers of industry standard quantities of Licensed Product for promotional purposes shall not be deemed a sale of such Licensed Product that gives rise to Net
Sales for purposes of this Section 1.11. 
 With respect to each Combination Product, Net Sales of the Licensed Product component of
such Combination Product shall be determined using the following formulae: 
 (a) If the Licensed Product and Other Actives
contained in the Combination Product are [***], then Net Sales shall be determined by multiplying the Net Sales of the Combination Product by [***]. 

(b) If the Licensed Product contained in the Combination Product is [***], then Net Sales shall be determined by [***]. 

(c) If neither the Licensed Product nor the Other Actives contained in the Combination Product are [***], the Parties shall in
good faith endeavor to agree upon the relative contribution of Licensed Product and Other Actives to such Combination Product in such market. By way of example, the parties may agree that relative contribution of Licensed Products and Other Actives
can be determined by examining the prices of Licensed Products and Other Actives in [***], where [***] are identified are similar with respect to all, or essentially all, of the following features: [***]. If the Parties are unable to reach
agreement, either Party may, on notice to the other Party, refer such matter to arbitration as provided in Section 11(b), below. 
 1.12
“Patent Expenses” shall mean all expenses (including, without limitation, legal fees) reasonably incurred by COH with respect to the prosecution or maintenance of the Patent Rights in either one of the Fields. 

1.13 “Patent Group 1” means: (i) those issued U.S. patents and pending patent applications shown on Exhibit A attached
hereto, (ii) any patent(s) issuing from divisionals, continuations, or continuations-in-part of any patent application from which either of the foregoing patent or patent applications claims priority, throughout the world, (iii) issued
patents and pending patent applications that claim inventions 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 4 - 

 CONFIDENTIAL 
  

conceived as a result of mutually agreed-upon research activities at COH sponsored by Zeta during [***], which inventions cover or claim the subject matter of any of the patents or pending
applications shown on Exhibit A, and (iv) patents and patent applications that are foreign counterparts, renewals, reissues, reexaminations or extensions of the foregoing (i) or (ii). 

1.14 “Patent Group 2” means: (i) those issued U.S. patents and pending patent applications shown on Exhibit B
attached hereto, (ii) any patent(s) issuing from divisionals, continuations, or continuations-in-part of any patent application from which either of the foregoing patent or patent applications claims priority, throughout the world,
(iii) issued patents and pending patent applications that claim inventions conceived as a result of mutually agreed-upon research activities at COH sponsored by Zeta during [***], which inventions cover or claim the subject matter of any of the
patents or pending applications shown on Exhibit B, and (iv) patents and patent applications that are foreign counterparts, renewals, reissues, reexaminations or extensions of the foregoing (i) or (ii). 

1.15 “Patent Rights” means any issued patent or pending patent application included in either Patent Group 1 or Patent Group
2. 
 1.16 “Second Qualified Financing” means one or more transactions which result in aggregate net cash proceeds to Zeta
of not less than $[***] (after payment of or accounting for all commissions, discounts, rebates, refunds or credits) in return for the issuance of membership units or other equity in Zeta. 

1.17 “Sublicense Revenues” means all consideration received by Zeta in return for the grant of rights to manufacture, use,
offer for sell or sell a Licensed Product, other than consideration in the form of: [***]. 
 1.18 “Third Parties” means a
person or entity that is not COH or Zeta or an Affiliate or sublicense of COH or Zeta. 
 1.19 “Valid Claim” means [***]
which: (i) has not expired, been revoked or cancelled, [***], (ii) has not been withdrawn, disclaimed, denied, admitted by the 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 5 - 

 CONFIDENTIAL 
  

owner or its successor or assigns to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise, and (iii) with respect to any particular pending patent application
[***], has not been pending in any country for more than [***] years from the earlier of the initial filing date of such patent application in such country or the international filing date of such patent application. 

 

	2.	LICENSE 

  

	 	2.1	License Grants. 

  

	 	(a)	COH grants to Zeta and Zeta accepts from COH an exclusive, worldwide royalty-bearing license under Patent Group 1 to manufacture, use, import, offer for sale and sell Licensed Product Group 1 in Field 1 and Field 2.

  

	 	(b)	COH grants to Zeta and Zeta accepts from COH an exclusive, worldwide royalty-bearing license under Patent Group 2 to manufacture, use, import, offer for sale and sell Licensed Product Group 2 in Field 2.

 The Parties acknowledge that the research leading to the creation of the Patent Rights was funded in part by the U.S.
Government. The license grants to Zeta pursuant to subsections (a) and (b), above, shall, as a result, be subject to the reserved rights of the U.S. Government. Such license grants shall also be as a reserved royalty-free right in favor of COH
to practice the Patent Rights for non-commercial clinical, educational and research purposes including, without limitation, use in research and clinical collaborations between COH and other not-for-profit institutions. 

 

	 	2.2	 Sub-licensing. Zeta shall have the right to sub-license its rights hereunder only with the prior written consent of COH, [***]. Sublicensees of
Zeta shall have no right to grant further sublicenses of the rights granted by Zeta hereunder and all such sublicenses shall expressly terminate upon the termination, for any reason, of this Agreement. At least [***] prior to entering into any
sublicense of its rights hereunder, Zeta shall provide to COH a draft of the proposed signature copy of such sublicense (including all referenced exhibits and schedules). If COH does

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 6 - 

 CONFIDENTIAL 
  

	 	
not object by notice to Zeta within such [***] period, COH shall be deemed [***]. Within [***] after entering into each approved sublicense, Zeta shall provide to COH a true and correct copy of
such sublicense in its final form. 

  

	 	2.3	Diligence. Zeta shall use reasonable efforts consistent with prudent business judgment in the development and commercialization of Licensed Products for the purposes authorized pursuant to Section 2.1,
above, throughout the world. On or before March 1 of each License Year starting with March 1, 2010, Zeta shall deliver to COH a written report setting forth [***] development and commercialization of Licensed Products during the preceding
License Year. 

 Without limiting the foregoing, Zeta (directly or through one or more sub-licensees) shall
reach each of the following “milestones” by the date specified. In the event that Zeta timely fails to reach any such milestone, this Agreement shall terminate immediately upon notice of termination by COH to Zeta, without the opportunity
for cure 
  

			
	 Milestone Event
	  	 Deadline

	(i) First Qualified Financing	  	180 days after the Effective Date
	(ii) Second Qualified Financing	  	December 15, 2015
	(iii) [***]	  	[***]
	(iv) [***]	  	[***]

 Milestones 2.3(iii) and (iv), above, may be extended by Zeta on notice to COH if [***]. 

 

	 	2.4	U.S. Manufacture. Zeta shall assure that all Licensed Products are, to the extent required by applicable law (including, without limitation, 35 U.S.C. Section 200 et seq. and 37 C.F.R. Section 401 et
seq.), substantially manufactured in the United States. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 7 - 

 CONFIDENTIAL 
  

	3.	COMPENSATION TO COH 

  

	 	3.1	Consideration for the Initiation of the License. As partial consideration for the issuance of the rights granted to Zeta herein, within [***] after the Effective Date, Zeta shall: (i) pay to COH $[***], and
(ii) issue to COH or its qualified designee(s) the amount of fully paid up and non-assessable Zeta Series B membership units issued to non-cash contributing members that is equivalent to [***] percent of the total outstanding membership units
calculated on a fully diluted basis (“COH’s Ownership Percentage Interest”). Zeta and COH or its designee(s) with respect to such shares shall enter into an agreement in form and substance reasonably acceptable to COH that shall
generally provide, inter alia: (i) COH’s Ownership Percentage Interest will not be less than [***] percent of the total outstanding members units calculated on a fully diluted basis to the extent that Zeta issues additional
membership units (“Anti-Dilution Right”) until such date when Zeta has obtained an aggregate minimum of $[***] through a Zeta Equity Financing (at which time the Anti-Dilution Right shall terminate in its entirely) and (ii) COH shall
be entitled to attend the meetings of the Zeta board of directors which advises the manager of Zeta and to timely receipt of all materials distributed to the members of the Zeta board of directors. The foregoing consideration is non-refundable and
is not creditable against any other amount payable by Zeta to COH under this Agreement. 

  

	 	3.2	License Maintenance Fee. On or before February 1 of each License Year, commencing with the 2010 License Year, Zeta shall pay to COH a license maintenance fee of $25,000. The license maintenance fee paid with
respect to a given License Year shall be non-refundable but shall be creditable against royalties actually due to COH with respect to sales of Licensed Products during such License Year. No payment shall be carried forward or credited against
royalties payable for any other License Year or credited against any other amounts due to COH hereunder. 

  

	 	3.3	Royalties. Zeta shall pay to COH a royalty equal to [***] percent of Net Sales [***]. No multiple royalties shall be payable to COH because a Licensed Product is covered by more than one claim in any patent
application or patent included in the Patent Rights. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 8 - 

 CONFIDENTIAL 
  

	 	3.4	Royalty Stacking. In the event that Zeta or a sublicense of Zeta is required, by contract, judgment or otherwise, to pay to a Third Party royalties or other consideration in return for the right to manufacture,
use, offer for sale, sell, import or export a Licensed Product, Zeta shall be entitled to off-set against [***] of the amount due to COH pursuant to Section 3.3, above, in a given calendar quarter and with respect to sales in a given country
[***] of the amount due to such Third Party that is in excess of [***] percent of Net Sales with respect to such Licensed Product in such calendar quarter; provided, however, that the royalty rate payable to COH pursuant to Section 3.3, above,
shall in no event be less than [***] percent of Net Sales. 

 By way of example, assume that Zeta’s Net
Sales of Licensed Product X in a given calendar quarter in country Y are $[***]. Further assume that Zeta owes to a Third Party a royalty of [***] percent with respect to such sales. In such instance, Zeta would be entitled to [***] and Zeta would
owe to COH $[***], i.e. [***] percent of $[***] (assuming that the royalty rate then in effect was [***] percent). By way of further example, assume that Zeta’s Net Sales of Licensed Product A in a given calendar quarter in country B are
$[***]. Further assume that Zeta owes to Third Parties total royalties of [***] percent with respect to such sales. Zeta would be entitled to offset against $[***] (i.e. [***] of the $[***] otherwise due pursuant to Section 3.3, assuming
that the royalty rate then in effect was [***] percent) [***] of the amount due to such Third Parties that is in excess of [***] percent of Net Sales, or $[***]. In such instance, Zeta’s total obligation to COH under Section 3.3 would be
$[***]. 
  

	 	3.5	 Sublicense Revenues. Until such time as Zeta, directly or through one or more sub-licensees, has expended an aggregate of at least $[***] in
direct and indirect costs related to the development and commercialization of Licensed Products, Zeta shall pay to COH [***] percent of all Sublicense Revenues. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 9 - 

 CONFIDENTIAL 
  

	 	
Thereafter, Zeta shall pay to COH [***] percent of all Sublicense Revenues. Payments shall be due to COH within [***] after the date Sublicense Revenues were received or credited to the benefit
of Zeta, whichever occurs first. With respect to Sublicense Revenues received in a form other than cash or cash equivalents, COH may, at its option, elect to take payment either [***] or based on the [***] of the consideration received by Zeta at
the time of receipt. 

  

	 	3.6	Manner and Timing of Payments. 

  

	 	(a)	Until such time as cumulative Net Sales in any calendar quarter reaches $[***], royalty payments shall be due and payable on or before March 1 of each License Year with respect to Net Sales occurring during the
preceding License Year. Once cumulative Net Sales in a calendar quarter first reach $[***], then – commencing with Net Sales occurring in the subsequent calendar quarter and in all calendar quarters thereafter – royalties shall be due and
payable within [***] after the last day of each calendar quarter with respect to Net Sales occurring during the preceding calendar quarter. All payments made by Zeta shall be sent to COH together with a written statement setting forth the following
information: [***]. 

  

	 	(b)	All royalties, fees or other payments due COH pursuant to this Agreement shall be calculated and paid in United States dollars. If the amount of any royalty, fee or payment is calculated, in whole or in part, based on
amounts stated in a currency other than United States dollars, prior to making the royalty calculation the foreign currency shall be converted into United States dollars using the closing buying rate for dollars published by The Wall Street
Journal on the last business day of the calendar quarter during which the royalty, fee or other payment accrued. 

  

	 	(c)	If any payment due under this Agreement is not paid when due, it shall bear interest from the due date until paid at the lesser of [***] percent per annum or the maximum rate allowable by law. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 10 - 

 CONFIDENTIAL 
  

	 	3.7	Books and Records. Zeta and each of its sub-licensees shall establish and maintain in the United States true and complete books of account, records, royalty statements, invoices, and other data containing all
particulars reasonably necessary for an independent determination of the royalties, fees and other amounts payable by Zeta to COH under this Agreement (“Records”) and the amounts expended by or on behalf of Zeta in the development and
commercialization of Licensed Products. The Records for each License Year shall be maintained for a period of [***] after the end of that License Year or [***] after the information contained in those Records first was provided to COH, whichever is
later. 

  

	 	3.8	Audit. COH shall have the right to appoint an independent certified public accountant reasonably acceptable to Zeta, to audit, inspect, copy, and make extracts from all Records to the extent necessary to verify
the accuracy of any payments made and statements furnished to COH. COH may exercise this right during normal business hours on [***]. In the event any such audit discloses an underpayment to COH, Zeta shall pay to COH the amount of any underpayment
together with interest as set forth at Section 3.6(c), above, within [***] of Zeta’s receipt of a notice describing the auditors findings. In the event any examination by COH discloses an overpayment to COH, the amount of such overpayment,
together with interest due thereon at the rate set forth in Section 3.6(c), above, shall be creditable by Zeta against amounts subsequently due to COH hereunder. If no further amounts are potentially due to COH hereunder as a result of the
termination or expiration of the term of this Agreement, COH shall pay to Zeta the amount of the overpayment together with accrued interest within [***] of COH’s receipt of a written notice describing the findings. 

The foregoing audit shall be [***]; provided, however, that in the event the audit reveals that the amount of underpayment by
Zeta for any calendar quarter or other applicable payment period exceeds [***] percent of the amount actually due to COH with respect to such calendar quarter or other applicable payment period [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 11 - 

 CONFIDENTIAL 
  

	4.	TERM AND TERMINATION 

  

	 	4.1	Term. Unless otherwise terminated pursuant to Section 4.2, the term of this Agreement shall commence on the Effective Date. Zeta’s obligation to pay royalties shall expire, on a country-by-country
basis, upon the expiration date of the last to expire of the Patent Rights in such country. The term of this Agreement shall expire upon the expiration of the last to expire of the Patent Rights anywhere in the world. 

 

	 	4.2	Termination. This Agreement may be terminated prior to the expiration of its term upon the happening of any of the following events: 

 

	 	(a)	By either Party if the other Party (the “Breaching Party”) shall materially breach this Agreement or otherwise fail to perform any material term, condition or obligation under this Agreement and that failure
is not cured within 30 days after written notice of such breach or failure to perform is received by the Breaching Party; 

  

	 	(b)	By COH immediately upon written notice to Zeta, if Zeta seeks to dissolve, liquidate all of its assets, or windup its business; or if Zeta ceases to do business in its entirety in the normal course, or if Zeta shall
commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now in effect, or seeking the appointment of a trustee,
receiver, liquidator, custodian or other similar official of it or any substantial part of its property; 

  

	 	(c)	 By COH immediately upon written notice to Zeta if an involuntary case or other proceeding shall be commenced against Zeta seeking liquidation,
reorganization or other relief with respect to it or its debts under any bankruptcy, insolvency or other similar law in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar

  
 - 12 - 

 CONFIDENTIAL 
  

	 	
official of it or any substantial part of its property, and such involuntary case remains unstayed and in effect for more than the greater of: (i) 90 days and (ii) such reasonable time
period necessary for Zeta to dismiss such involuntary case to the extent such involuntary case remains unstayed and in effect for more than such 90-day period solely due to the dilatory actions by a Third Party to prevent Zeta from properly
dismissing the same; or 

  

	 	(d)	By COH as provided in Section 2.3, above. 

  

	 	4.3	Duties Upon Termination. Upon termination of this Agreement, Zeta shall immediately cease to import, make, offer to sell, sell or use Licensed Products. Within [***] after termination Zeta shall pay to COH all
royalties, license maintenance fees, or other payment amounts due under this Agreement that accrued prior to termination. 

  

	 	4.4	Survival. Sections 3.7, 3.8, 4.3, 4.4, 6.4, 7.3_8.1 and 8.2 and Articles 9, 10, 11, 13, 16, 18, 19 and 21 of this Agreement shall survive the termination or expiration of the term of this Agreement [***].

  

	5.	REPRESENTATIONS AND WARRANTIES 

 5.1 Mutual Representations and
Warranties. Each Party represents and warrants to the other Party that, as of the Effective Date: 
  

	 	(a)	it is a duly organized, validly existing and in good standing under the laws of its state of organization; 

  

	 	(b)	it has the right and authority to execute and deliver this Agreement and to perform its obligations (including, in the case of COH, the grant of the licenses) as contemplated hereunder; 

 

	 	(c)	this Agreement is a legal, valid and binding agreement of such Party and enforceable against it; 

  

	 	(d)	the execution and delivery of this Agreement will not breach any governing instrument or agreement of such Party or, to such Party’s knowledge, any statute, regulation or any other restriction upon such Party; and,

  

	 	(e)	it has secured all requisite authorizations and approvals necessary to the execution, delivery and performance of this Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 13 - 

 CONFIDENTIAL 
  

5.2 COH Representations and Warranties. COH represents and warrants to Zeta that, as of the Effective Date: 

 

	 	(a)	[***]; 

  

	 	(b)	COH has not previously granted any rights in the Patent Rights that are inconsistent with the rights and licenses granted to Zeta herein; 

 

	 	(c)	[***], there is not pending [***], any [***] litigation to which COH is a party contesting the ownership, derivation, inventorship, validity or right to use in either of the Fields any of the Patent Rights;

  

	 	(d)	[***], COH has not received any written notice of infringement with respect to the exercise of the Patent Rights in either of the Fields; and 

 

	 	(e)	[***]. 

  

	6.	LIMITATIONS ON WARRANTIES AND REMEDIES 

  

	 	6.1	EXCEPT AS EXPRESSLY SET FORTH IN SECTION 5, ABOVE, COH MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO: (i) ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE, OR (ii) ANY REPRESENTATION OR WARRANTY WITH RESPECT TO THE VALIDITY OR SCOPE, OR OWNERSHIP OF THE PATENT RIGHTS. 

  

	 	6.2	 COH MAKES NO REPRESENTATION OR WARRANTY WITH RESPECT TO THE LICENSED PRODUCTS OR THE INFRINGEMENT BY THE SAME OF ANY PROPRIETARY RIGHT, OR ANY
REPRESENTATION OR WARRANTY WITH RESPECT TO THE 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 14 - 

 CONFIDENTIAL 
  

	 	
ABSENCE OF ANY DEFECT IN THE LICENSED PRODUCTS OR PATENT RIGHTS. ZETA IS AWARE THAT IN ORDER TO PRACTICE ANY OR ALL OF THE PATENT RIGHTS, IT MAY BE NECESSARY TO OBTAIN ADDITIONAL LICENSES TO
OTHER PATENTS OR INTELLECTUAL PROPERTY. 

  

	 	6.3	ZETA HAS HAD THE OPPORTUNITY TO REVIEW OR HAS REVIEWED THE PATENT RIGHTS TO VERIFY THE SUITABILITY OF THE PATENT RIGHTS FOR ZETA’S INTENDED PURPOSE AND IS NOT RELYING ON ANY STATEMENTS OF COH WITH RESPECT TO
SUCH VERIFICATION. 

  

	 	6.4	IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES, INCLUDING, BUT NOT LIMITED TO, ANY LOST PROFITS OR OPPORTUNITIES, ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH
THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. [***], IN NO EVENT SHALL COH’S LIABILITY TO ZETA UNDER OR RELATING TO THIS AGREEMENT (WHETHER IN TORT, CONTRACT, QUANTUM MERUIT, OR
OTHERWISE) EXCEED [***]. IN NO EVENT SHALL COH BE LIABLE TO ZETA FOR ANY DAMAGES ARISING OUT OF, RELATED TO, OR IN CONNECTION WITH THE MANUFACTURE, SALE, USE OR OFFER FOR SALE OF LICENSED PRODUCTS OR EXPLOITATION OF THE PATENT RIGHTS.

  

	7.	PATENT RIGHTS, LICENSED PRODUCTS; INFRINGEMENT ACTIONS; TRADE DRESS 

  

	 	7.1	Patent Rights 

  

	 	7.1.1	 COH shall have the sole and absolute discretion to control the preparation, filing, prosecution and maintenance and assertion and defense of the
Patent Rights, using 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 15 - 

 CONFIDENTIAL 
  

	 	
patent counsel selected by COH and approved by Zeta, such approval not to be unreasonably withheld or delayed. Notwithstanding the foregoing, COH (directly or through its patent counsel) shall
maintain patents and prosecute patent applications and use reasonable efforts to (i) consult in a timely manner with Zeta as to the preparation, filing, prosecution, maintenance, assertion and defense of the Patent Rights within Field 1 and
Field 2, and (ii) promptly furnish to Zeta copies of all correspondence between COH and the U.S. Patent and Trademark Office or its foreign counterparts related to the Patent Rights. 

 

	 	7.1.2	The Parties acknowledge that as of the Effective Date, COH has incurred a total of $[***] in Patent Expenses. This total amount shall be due and payable by Zeta to COH as follows: On or before [***], Zeta shall pay to
COH $[***]. On or before [***], Zeta shall pay to COH an additional $[***]. On or before the [***], Zeta shall pay to COH an additional $[***]. On or before [***], Zeta shall pay to COH the balance of the Patent Expenses incurred by COH prior to the
Effective Date. 

  

	 	7.1.3	In addition to the amounts due pursuant to Section 7.1.2, above, following the Effective Date Zeta shall reimburse COH for [***] incurred by COH. Each such payment shall be due within [***] after receipt by Zeta of
an invoice from COH’s [***]; provided, however, that the Parties shall in good faith cooperate in the event that Zeta notifies COH within such [***] period that it, in good faith, disputes the amounts claimed pursuant to any such invoice.

  

	 	7.2	Licensed Products. The Licensed Products and the entire right, title and interest in and to all discoveries, improvements, processes, formulas, data, inventions, enhancements, know-how and trade secrets,
patentable or otherwise, that arise from activities under this Agreement or that are necessary or useful in connection with obtaining regulatory approval, manufacture, marketing, promotion, sale, import or export of Licensed Products, and that were
or are developed or invented by Zeta (“Zeta Inventions”) shall be owned solely by Zeta (except for any Patent Rights), and COH shall not acquire any right, title, and interest in or to any Licensed Products and Zeta Inventions.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 16 - 

 CONFIDENTIAL 
  

	 	7.3	Each Party shall promptly disclose to the other any infringement of the Patent Rights in Field 1 or Field 2 of which it becomes aware. COH, in consultation with Zeta, shall have the sole right to assert the Patent
Rights to abate any such infringement and, further, shall have the sole right to defend the Patent Rights against allegations of invalidity or other Third Party claims. 

 

	 	7.4	In the event that [***] and, as a result [***] an unlicensed competitor of Zeta’s captures [***] percent or more of a market previously established by Zeta for a Licensed Product in a given country, Zeta shall be
entitled to a [***] percent reduction in the amount of royalties that would otherwise be payable to COH with respect to such Licensed Product [***] from such [***] percent or great market share. 

 

	 	7.5	Communications between Zeta and COH with respect to the abatement of Third Party infringement of the Patent Rights or the defense of the Patent Rights against a Third Party challenge shall be deemed confidential as
between the Parties as shall, to the extent lawful, made in furtherance of joint prosecution or defense or among parties having common legal interests. 

  

	 	7.6	Zeta shall have the right to determine appropriate trademark, trade dress, and other related intellectual property usage in connection with marketing Licensed Products under this Agreement. Zeta shall have the exclusive
right to use trademarks use any trademarks in connection with marketing Licensed Products under this Agreement. 

  

	8.	INDEMNIFICATION. 

 8.1 Zeta shall at all times during the term of this Agreement
and thereafter, indemnify, defend, and hold COH and its trustees, directors, officers, employees and agents (“Indemnitees”), harmless from and against all claims, suits, liabilities, losses, damages, proceedings, demands, expenses
(including reasonable legal expenses and reasonable attorneys’ fees) and costs (“Claims”), related in any way to [***]. Zeta 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 17 - 

 CONFIDENTIAL 
  

shall not be obligated, however, to indemnify Indemnitees for that portion of any Claim determined to arise directly from the gross negligence or a willful act or omission by an Indemnitee, or a
material uncured breach by COH of any of its covenants, representations or warranties set forth in Section 5, above. 
 8.2 The
indemnification obligation set forth in Section 8.1, above, is subject to the following: [***]. 
  

	9.	INSURANCE 

 Zeta shall obtain and maintain, during the term of this Agreement (and
covering claims made for a period of three years thereafter), Comprehensive General Liability Insurance, including Products Liability Insurance, with a reputable, secure insurance carrier(s), or via a program of self-insurance, to cover acts or
omissions concerning the production, manufacture, sale, use, importation, consumption, promotion, distribution, advertisement or other application of Licensed Products or services by Zeta and to cover Zeta’s indemnification obligations set
forth in Section 8, above. The amount of such insurance shall be at least [***]. 
  

	10.	NOTICE 

 Any notice or other communication required or permitted shall be in
writing and shall be deemed to have been received on the delivery date if personally delivered, sent by overnight courier, or sent by facsimile (with written confirmation of transmission forwarded the same day by mail); or, if mailed, seventy-two
hours after having been placed in the United States mail, registered or certified, postage prepaid, addressed to the Party to whom it is directed at the address set forth below: 

If to COH: 
 City of Hope 

1500 East Duarte Road 
 Duarte,
CA 91010-3000 
 Attention: Sr. Vice President for Technology Development 

Facsimile: (626) 256-8730 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 18 - 

 CONFIDENTIAL 
  

With a copy to: 
 City of Hope

 Office of General Counsel 

1500 East Duarte Road 
 Duarte,
CA 91010-3000 
 Facsimile: (626) 301-8863 

If to Zeta: 
 ZetaRx LLC 

c/o Benmore Capital 
 9701
Wilshire Boulevard, Suite 1000 
 Beverly Hills, CA 90212 

Facsimile: (310) 476-5396 

Either Party may change the address to which notices are to be addressed by giving the other Party written notice in the manner described in
this Section 10. 
  

	11.	GOVERNING LAW AND DISPUTE RESOLUTION 

 (a) The validity, construction, and
interpretation of this Agreement shall be governed in all respects by, and the Agreement shall be construed in accordance with, the laws of the State of California, exclusive of choice of law principles. Each Party consents to service of process in
any action or proceeding by mailing a copy of such process by United States mail, registered or certified, postage prepaid, return receipt to the addresses listed in Section 10. Except as expressly provided in subsection (b), below, all
disputes, claims or proceedings between the Parties arising under this Agreement shall be brought to trial or other adjudication in the state or federal courts sitting in Los Angeles County, California. Subject to any right of appeal, both Parties
agree that any judgment rendered shall be conclusive, binding, and enforceable by any court of competent jurisdiction. In the event of litigation or other proceedings arising out of or relating to this Agreement (including proceedings in
bankruptcy), the prevailing Party shall be entitled to recover its reasonable attorneys’ fees and expenses of litigation. 
 (b) All
disputes arising between the Parties with respect to the relative contribution of Licensed Product and Other Actives to a Combination Product as contemplated by 

  
 - 19 - 

 CONFIDENTIAL 
  

Section 1.10, above, shall be resolved by binding arbitration in Los Angeles County, California, before a single independent arbitrator acting pursuant to the Commercial Rules of the
American Arbitration Association (“AAA”). If the Parties are unable to agree as to the identity of such arbitrator, at the request of either Party such arbitrator shall be appointed by the President of the AAA. 

 

	12.	FORCE MAJEURE 

 Except for the obligation to pay royalties and other sums under
this Agreement when due, neither Zeta nor COH shall be liable for non-performance caused by any circumstance beyond its reasonable control, including, without limitation, the following: war, floods, earthquakes, other acts of God, industrial
disputes, civil disobedience, acts of terrorism, strikes, fire, mobilization, changes in governmental regulation or interpretation, requisition, embargo, restriction and shortage of transport facilities, fuel, energy or supplies. A Party claiming
the benefit of such an excuse agrees to notify the other Party promptly in writing of any such delay or failure in performance, and to resume performance as soon as is reasonably practicable. Notwithstanding the foregoing, no obligation of a Party
may be delayed by more than three months in a single instance or six months in the aggregate by virtue of force majeure. 
  

	13.	PUBLICATION 

 Except to the extent required by law, neither Party may make a
public announcement with respect to the existence or terms of this Agreement without the approval of the other Party, which approval shall not be unreasonably withheld or delayed. The substance of any such public announcement, once made, may be
republished by either Party without the further approval of the other Party. Except with respect to such an approved public announcement or as otherwise required by law, neither Party shall use the name of the other Party or of any staff member or
employee of the other Party in any announcement publication, or presentation which relates to the subject matter of this Agreement without the prior written consent of the other Party. Except as expressly provided in this Article 13 or in Article
16, below, each Party shall keep the existence and terms and conditions of this Agreement confidential. 

  
 - 20 - 

 CONFIDENTIAL 
  

	14.	RELATIONSHIP OF THE PARTIES 

 The relationship between the Parties under this
Agreement is that of licensee and licensor. Neither Party shall have any right or authority whatsoever to assume or to create any obligation or responsibility of the other Party or to bind the other Party in any manner. 

 

	15.	SEVERABLE PROVISIONS 

 The provisions of this Agreement are severable and if any
one or more provisions may be determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall nevertheless be binding and enforceable.

  

	16.	CONFIDENTIAL INFORMATION 

 Each Party shall hold in confidence any Confidential
Information disclosed by the other Party hereunder, and agrees not to disclose any Confidential Information to any third party without the express written consent of the other Party; provided, however, that either Party may disclose such
information: (a) in confidence, to its employees, consultants, attorneys, auditors and professional advisors with a need to know and who agree to appropriate restrictions on use or disclosure other than to further the purposes of this
Agreement, and (b) to a court or tribunal as necessary or useful to enforce this Agreement. Each Party shall use the same degree of care in protecting Confidential Information of the other Party as it uses for its own information of like
importance, but not less than a reasonable degree of care. Each Party will use Confidential Information only for purposes of furthering the purposes of this Agreement. With respect to any Confidential Information that is revealed by a Party to the
other Party, this confidentiality obligation will remain in force for a period of [***] following the expiration or termination of this Agreement. Notwithstanding any other provision of this Agreement, a Party may disclose Confidential Information
which is required to be disclosed by law, rule or regulation (including applicable regulations of any securities exchange), or any, administrative or legal process; provided, however, that the Party proposing to make such disclosure shall give
prompt prior written notice to the other Party and agrees to consult with the other Party in good faith regarding the scope of such disclosure. Furthermore, in 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 21 - 

 CONFIDENTIAL 
  

the case of any administrative or legal process, the Party proposing to make such disclosure shall provide reasonable cooperation to the other Party, at the other Party’s expense, in the
latter Party’s efforts to challenge the basis for such compelled disclosure or limit the scope of disclosure of such information, as the disclosing Party may deem appropriate. 

 

	17.	ASSIGNMENT 

 Zeta shall not assign or transfer this Agreement, nor any of its
rights or obligations hereunder, in any manner (including by operation of law) without the prior written consent of COH, which consent COH may withhold in its sole discretion [***]. Any purported assignment inconsistent with this Section 17
shall be void. 
  

	18.	HEADINGS 

 Section and subsection headings are not to be considered part of this
Agreement and are included solely for convenience and reference and in no way define, limit, or describe the scope of this Agreement or the intent of any provision. 
  

	19.	NO CONSTRUCTION AGAINST DRAFTER 

 No provision of the Agreement, or any document
delivered pursuant to the Agreement, shall be construed against any party, merely because that party drafted that provision or document. 
  

	20.	PATENT MARKING 

 Zeta and its sub-licensees shall mark all Licensed Products in
accordance with all applicable patent marking laws. Without limiting the foregoing, Zeta shall require that the packaging of each Licensed Product clearly discloses that such Licensed Product is subject to pending and/or issued patents, as
applicable. 
  

	21.	ENTIRE AGREEMENT 

 This Agreement embodies and sets forth the entire agreement and
understanding of the Parties and supersedes all prior oral and written agreements, understandings or arrangements relating to the subject matter of this Agreement. Neither Party shall be entitled to rely on any agreement, understanding or
arrangement that is not expressly set forth in this Agreement. This Agreement shall not be amended, modified, varied or supplemented except in writing signed by duly authorized representatives of the Parties. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 22 - 

 CONFIDENTIAL 
  

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the date and year first set forth above. 

 

									
	ZETARX LLC	 		 	CITY OF HOPE
					
	By:	 	 /s/ Jack Kavanaugh
	 		 	By:	 	 /s/ Larry A. Couture

	Its:	 	Manager	 		 		 	Larry A. Couture PhD
		 		 		 		 	Its: Sr. VP, Applied Technology Development
					
		 		 		 	By:	 	 /s/ Michael A. Friedman

		 		 		 		 	Michael A. Friedman M.D.
		 		 		 		 	Its: President and Chief Executive Officer

  
 - 23 - 

 CONFIDENTIAL 
  

EXHIBIT A 
  

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 - END OF EXHIBIT A - 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 24 - 

 CONFIDENTIAL 
  

EXHIBIT B 
  

											
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
						
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 - END OF EXHIBIT B- 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 25 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]